Investigation Of Baff Expression And Signaling Pathway From Helicobacter-infected Gastric Epithelial Cells On Molecular Level by Karayılan, Miray
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
M.Sc. THESIS 
                                                     Miray KARAYILAN 
INVESTIGATION OF BAFF EXPRESSION AND SIGNALING PATHWAY IN 
HELICOBACTER-INFECTED GASTRIC EPITHELIAL CELLS ON 
MOLECULAR LEVEL 
 
AUGUST 2014 
 
Department of Molecular Biology-Genetics and Biotechnology 
 
Molecular Biology-Genetics and Biotechnology Programme 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
AUGUST 2014 
 
Department of Molecular Biology-Genetics and Biotechnology 
 
Molecular Biology-Genetics and Biotechnology Programme 
 
 
 
 
 
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
 
 
INVESTIGATION OF BAFF EXPRESSION AND SIGNALING PATHWAY IN 
 HELICOBACTER-INFECTED GASTRIC EPITHELIAL CELLS ON 
 MOLECULAR LEVEL 
 
M.Sc. THESIS 
Miray KARAYILAN 
(521111122) 
Thesis Advisor: Prof.Dr. Ayça SAYI YAZGAN 
v 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
AĞUSTOS 2014 
İSTANBUL TEKNİK ÜNİVERSİTESİ  FEN BİLİMLERİ ENSTİTÜSÜ 
HELİKOBAKTER – İNFEKTE MİDE EPİTEL HÜCRELERİNDEN BAFF 
ÜRETİMİNİN VE SİNYAL YOLAĞININ MOLEKÜLER DÜZEYDE 
ARAŞTIRILMASI  
YÜKSEK LİSANS TEZİ 
Miray KARAYILAN 
(521111122) 
Moleküler Biyoloji-Genetik ve Biyoteknoloji Anabilim Dalı 
 
Moleküler Biyoloji-Genetik ve Biyoteknoloji Programı 
 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
Tez Danışmanı: Doç. Dr. Ayça SAYI YAZGAN 
 vi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
 
v 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis Advisor:  Assoc. Prof. Dr. Ayça Sayı YAZGAN         ........................ 
 Istanbul Technical University 
Jury Members:        Assist.Prof.Dr. Aslı Kumbasar                     .........................
             Istanbul Technical University  
   Istanbul Technical University 
        Assoc. Prof. Dr. Nesrin Özören                    ........................ 
        Boğaziçi University 
Miray KARAYILAN, a M.Sc. student of ITU Graduate School of Science, 
Engineering and Technology student ID 521111122, successfully defended the 
thesis entitled “INVESTIGATION OF BAFF EXPRESSION AND SIGNALING 
PATHWAY IN HELICOBACTER-INFECTED GASTRIC EPITHELIAL 
CELL ON MOLECULAR LEVEL”, which she prepared after fulfilling the 
requirements specified in the associated legislations, before the jury whose signatures 
are below. 
 
 
 
Date of Submission: 13 August 2014 
Date of Defense: 22 August 2014  
 
 vi 
 
 
 vii 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
To my family and friends, 
 
 
 
 
 
 
 
 
 
 
 viii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
 
FOREWORD 
 
First, I would like to express my deep gratitude to my advisor, Assoc.Prof.Dr.Ayça 
SAYI YAZGAN for her guidance, patience, advices and encouragement. She was 
always there for me in my best and worst moments of my last 3 years. I would also 
thank you to my committee members Assist.Prof.Dr.Aslı KUMBASAR and Assoc. 
Prof.Dr.Nesrin ÖZÖREN for devoting their precious time to evaluate my thesis.  
I would like to much than thank you to my laboratory mates Nesteren MANSUR and 
Emre SOFYALI. I couldn’t image this 3 years without you. Thank you for being 
more than lab mates from the first day and standing always by me in and out of the 
lab. I shared lots of incredible and unforgettable moments with you. 
I am also grateful to Sinem ÖKTEM OKULLU and Tuğba KIZILBOĞA for their 
endless support, good- energy and great friendship. I had wonderful fun moments 
with you in and out of MOBGAM. I would also thank to other ASY LAB members: 
Zeynep ESENCAN, Tuba BARUT Aslı KORKMAZ, Sawsan SAID and Mantasha 
TABASSUM for their friendship. I want to express my thanks to Cem ÇELĠK for his 
support, Salih DEMĠR for humouring me, Koray KIRIMTAY for his help in 
anything and Hilal SARAÇ for being a lovely and amusing lab mate for a short 
while. 
Specials thanks to Aslı GÜRLEN, Miray GĠRGĠN, Ġdil SOYER and Begüm 
BOZANOĞLU for being my best friends since more than 12-20 years. I am very 
lucky to have wonderful unbiological sisters like you.  
I also want to express my thanks to Okan ARMAĞAN for his infinite moral support, 
knowledge and for being more than tennis coach for me.  
Finally, I am indebted to my mother; Nuray KARAYILAN, my father; Salim 
KARAYILAN, my sister; Nurgül KARAYILAN ÇETĠN, Metin ÇETĠN, Ġrem 
NAZLI KARAYILAN and my lovely brother; Suat KARAYILAN for their endless 
love, support, couragement throughout my life. Only if you are there for me, 
everything can be possible. I would also like to thank you to my loves, nephews, Efe 
ÇETĠN and Ege ÇETĠN for making me laugh and feel wonderful anytime especially 
in my bad times. I dedicate my thesis to my family for standing me in whole of my 
life. 
 
 
August 2014                                                                                 Miray KARAYILAN 
                         (Molecular Biologist                           
                                                                                                           and Genetics) 
 
 
 x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
 
TABLE OF CONTENT 
 
                  Page 
 
FOREWORD  ............................................................................................................ ix 
ABBREVIATIONS  ................................................................................................. xv 
LIST OF TABLES  ................................................................................................. xix 
LIST OF FIGURES  ............................................................................................... xxi 
SUMMARY  .......................................................................................................... xxiii 
ÖZET ..................................................................................................................... xxvii 
1.INTRODUCTION  .................................................................................................. 1 
   1.1 Helicobacter pylori  ............................................................................................ 1 
   1.2 Helicobacter pylori Virulence Factors  ............................................................... 2 
       1.2.1 The H.pylori cag Pathogenicity island  ........................................................ 3 
              1.2.1.1 CagA virulence factor  ....................................................................... 3 
              1.2.1.2 Other virulence factors in cagPAI  ..................................................... 4 
       1.2.2 VacA (vacuolating cytotoxin A) virulence factor  ....................................... 4 
   1.3 Cag A Translocation via Type IV Secretion System  ......................................... 5 
   1.4 B Cell Activating Factor (BAFF) ........................................................................ 6  
   1.5 A Proliferation Inducing Ligand (APRIL)  ......................................................... 7 
   1.6 Receptors of BAFF & APRIL  ............................................................................ 8 
   1.7 Innate Immunity ................................................................................................ 10  
       1.7.1 Toll-like Receptors  .................................................................................... 11 
       1.7.2 NOD-like Receptors  .................................................................................. 12 
              1.7.2.1 NOD1  .............................................................................................. 13 
       1.7.3 Interferon Regulatory Factor 7 (IRF7) ....................................................... 16 
       1.7.4 Interferon-beta (IFN- ) .............................................................................. 16 
   1.8 The JAK/STAT Signalling Pathway  ................................................................ 17 
1.9 Aim of the Study ................................................................................................ 18  
2.MATERIAL AND METHODS  ........................................................................... 19 
   2.1 Materials  ........................................................................................................... 19 
2.1.1 Helicobacter pylori strains  ........................................................................ 19 
       2.1.2 KATO-III Cell Line ................................................................................... 21 
       2.1.3 Buffers and solutions ................................................................................. 21  
2.1.3.1Cell culture ........................................................................................ 21 
       2.1.4 Agarose Gel Electrophoresis  ..................................................................... 21 
       2.1.5 Chemicals  .................................................................................................. 22 
       2.1.6 Protein isolation  ........................................................................................ 23 
       2.1.7 Western Blotting  ....................................................................................... 24 
       2.1.8 Primers  ...................................................................................................... 26 
       2.1.9 Antibodies and Inhibitor ............................................................................ 26 
       2.1.10 Equipment  ............................................................................................... 27 
       2.1.11 Commercial kits  ...................................................................................... 29 
 xii 
 2.2 Methods  .............................................................................................................. 29 
      2.2.1 Maintenances of Helicobacter pylori species  ............................................ 29 
      2.2.2 Growth of Helicobacter pylori strains ........................................................ 30 
              2.2.2.1 Colombia agar preparation   ............................................................. 30 
              2.2.2.2 Liquid culture  .................................................................................. 30 
      2.2.3 Sonication of Helicobacter pylori strains .................................................... 30 
      2.2.4 Protein Bicinchoninic Acid (BCA) Assay  ................................................. 30 
      2.2.5 Cell Culture  ................................................................................................ 31 
2.2.5.1 Maintenance of KATO-III Cell Lines  ............................................. 31 
              2.2.5.2 Cell thawing  .................................................................................... 31 
              2.2.5.3 Cell passage  ..................................................................................... 31 
              2.2.5.4 Cell freezing ..................................................................................... 31 
              2.2.5.5 Cell counting  ................................................................................... 32 
              2.2.5.6 Treatment of KATO-III cells with Helicobacter pylori sonicates ... 32 
              2.2.5.7 Cell Harvesting  ................................................................................ 32 
      2.2.6 RNA isolation from eukaryotic KATO-III cells  ........................................ 33 
      2.2.7 cDNA Synthesis .......................................................................................... 33 
      2.2.8 Primer design ............................................................................................... 34 
      2.2.9 18S rRNA PCR ........................................................................................... 34 
      2.2.10 Agarose Gel Electrophoresis  .................................................................... 35 
      2.2.11 Real-time PCR .......................................................................................... 36 
      2.2.12 Protein isolation ......................................................................................... 37  
      2.2.13 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western   
                 Blotting ...................................................................................................... 37 
      2.2.14 BAFF ELISA ............................................................................................ 38 
      2.2.15 Densitometric analyses .............................................................................. 39 
 2.2.16 Statistical analyses ..................................................................................... 40 
3. RESULTS  ............................................................................................................. 41 
    3.1 Effect of H.pylori on BAFF expression in KATO-III cells  ............................ 41 
         3.1.1 Investigation of BAFF expression from H.pylori G27 WT sonicate-  
                  treated KATO-III gastric epithelial cells in a time-dependent manner .... 41 
         3.1.2 Effect of H.pylori virulence factor Cag A on BAFF expression in  
                  KATO-III cells ......................................................................................... 42  
   3.2 Effect of H.pylori sonicate-  treated KATO-III cells on BAFF production.... 43 
   3.2.1 H.pylori sonicate induced membrane-bound and soluble BAFF 
                   production  ............................................................................................... 43 
          3.2.2 Effect of H.pylori sonicate on BAFF secretion in KATO-III cells ......... 44 
     3.3 Effect of H.pylori on APRIL expression in KATO-III cells  .......................... 46 
          3.3.1 Investigation of APRIL expression from H.pylori G27 WT sonicate-  
                   treated KATO-III gastric epithelial cells in a time-dependent manner  .. 46  
          3.3.2 Effect of H.pylori virulence factor Cag A on APRIL expression in  
                   KATO-III cells ........................................................................................ 47 
   3.4 Effect of H.pylori sonicate- treated KATO-III cells on APRIL 
           production  ....................................................................................................... 48 
          3.4.1 Effect of H.pylori virulence factor Cag A on APRIL production ........... 48  
      3.5 H.pylori G27 WT sonicate induces NOD1 expression in KATO-III cells .... 49 
          3.5.1 Effect of H.pylori G27 WT sonicate on NOD1 expression in a  
                   time- dependent manner  ......................................................................... 49 
          3.5.2 Effect of H.pylori virulence factor Cag A on NOD1 expression  ........... 50 
      
 xiii 
3.6 Effect of H.pylori G27 WT sonicate on IRF7 expression in KATO-III cells   .... 52 
     3.6.1 Investigation of IRF7 expression from H.pylori G27 WT sonicate- treated         
             KATO-III gastric epithelial cells in a time-dependent manner ..................... 52 
     3.6.2 Effect of H.pylori virulence factor Cag A on IRF7 expression  .................. 53 
3.7 Role of H.pylori sonicates on IFN-β expressions in KATO-III cells   ................ 54 
     3.7.1 Investigation of IFN-β expression from H.pylori G27 WT sonicate- 
             treated KATO-III gastric epithelial cells in a time-dependent manner   ....... 54 
     3.7.2 Effect of H.pylori virulence factor Cag A on IFN- β expression  ................ 55 
3.8 Investigation of JAK/STAT signalling pathway in H.pylori G27 WT  
      sonicate- treated KATO-III cells  ......................................................................... 56 
     3.8.1 Effect of H.pylori G27 WT sonicate on STAT1 Phosphorylation   ............. 56 
     3.8.2 Effect of JAKI on BAFF expression ............................................................ 58 
     3.8.3 Effect of JAKI on BAFF production ............................................................ 59 
     3.8.4 Investigation of JAKI on BAFF secretion  .................................................. 61 
     3.8.5 Effect of JAKI on APRIL expression  ......................................................... 62 
     3.8.6 Effect of JAKI on APRIL production   ........................................................ 63 
     3.8.7 Effect of JAKI on NOD1 expression  .......................................................... 64 
     3.8.8 Effect of JAKI on the expression of IRF7  .................................................. 65 
     3.8.9 Role of JAKI on IFN-β expression .............................................................. 67 
4. DISCUSSION AND CONCLUSION  ................................................................ 69 
REFERENCES  ........................................................................................................ 73 
CURRICULUM VITAE  ......................................................................................... 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
 
 
 
 
 
 
 
 
 
 
 xv 
 
ABBREVIATIONS 
 
Μg            : Microgram 
μM            : Micromolar 
μm        : Micrometer 
BAFF     : delta BAFF 
APRIL   : delta APRIL 
AP-1          : Activator factor-1  
APC          : Antigen presenting cell 
APRIL      : A proliferation inducing ligand 
bp              : Base pair 
BabA         : Blood group antigen binding adhesion 
BAFF        : B cell activating factor 
BAFF-R    : BAFF Receptor 
BCA          : Bicinchoninic Acid 
BCMA      : B cell maturation antigen 
BIR           : Baculoviral inhibitor of apoptosis repeat 
BSA          : Bovine Serum Albumin 
Cag A       : Cytotoxin- asssociated gene –A 
Cag E       : Cytotoxin -asssociated gene –E 
cagPAI     : cag Pathogenicity island 
Cag Y       : Cytotoxin- asssociated gene –Y 
Cag I        : Cytotoxin -asssociated gene –I 
Cag L       : Cytotoxin -asssociated gene-L 
CARD      : Caspase activation and recruitment domain 
cDNA       : Complementary DNA 
CIITA      : Class II, major histocompatibility complex, transactivator 
CLR         : C-type lectin like receptor 
cm
2
           : Centimeter square 
CRD         : Cystein rich domain 
Csk           : C-terminal Src kinase 
Ct             : Cycle threshold 
DAMP     : Danger-associated molecular pattern 
DMEM    : Dulbecco’s modified Eagle medium  
DMSO     : Dimethyl sulfoxide 
DNA        : Deoxyribonucleic acid 
dNTP       : Deoxyribonucleotide 
dsRNA     : Double- stranded RNA 
EAE         : Experimental autoimmune encephalomyelitis 
EDTA      : Ethylenediaminetetraacetic acid 
ELISA     : Enzyme-Linked Immunosorbent Assay 
FBS         : Fetal Bovine Serum 
g     : Gram 
h      : Hour 
 xvi 
H.pylori   : Helicobacter pylori 
HSP   : Heparin sulphated proteoglycan 
IFN   : Interferon 
IFN-   : Interferon- alpha 
IFN-    : Interferon –beta 
IFN-    : Interferon –gamma 
IFNAR  : Interferon alpha / beta receptor alpha chain 
IFNGR  : Interferon gamma receptor 
IL-8    : Interleukin-8 
ISGF3  : Interferon stimulated gene factor-3 
IRF7    : Interferon regulatory transcription factor 7 
iE-DAP   : -d-glutamyl-meso-diaminopimelic acid 
JAK     : Janus Kinase 
JAK I    : Janus Kinase Inhibitor 
JNK     : c-Jun N-terminal Kinase 
kbp     : Kilo base pair 
kDa     : Kilo dalton 
L        : Liter 
LPS    : Lipopolysaccharide 
LRR     : Leucine rich repeat 
M    : Molar 
Mal    : MyD88-adapter –like 
MALT    : Mucosa-associated lymphoid tissue lymphoma  
MAPK    : Mitogen Activating Protein Kinase 
MDP      : muramyl di-peptide 
min       : minute 
mBAFF      : membrane –bound BAFF 
mL         : Mililiter 
mM             : Milimolar 
mm         : Milimeter 
MM            : Multiple myeloma 
mRNA        : Messenger Ribonucleic Acid 
MyD88       : Myeloid Differentiation primary response gene -88 
MZ          : Marginal zone 
NFAT         : Nuclear factor activated T cell 
NF- B         : Nuclear factor-kappa B 
ng          : Nanogram 
NHL           : Non Hodgkins lymphoma 
NLR         : Nod-like receptor 
nm          : Nanometer 
nM          : Nanomolar 
NOD1         : Nucleotide oligomerization domain-1 
NOD2         : Nucleotide oligomerization domain-2 
OipA         : Outer inflammatory protein A 
OMP          : Outer membrane protein  
OMV          : Outer membrane vesicle 
PCR          : Polymerase Chain Reaction 
pH   : Power of Hydrogen 
RICK  : Receptor-interacting serine/threonine-protein kinase 2 
PAMP  : Pathogen-associated molecular patter 
 xvii 
PGN  : Peptidoglycan 
PRR  : Pattern –recognation receptor 
PYD  : Pyrin domain 
qRT-PCR  : Quantitative Real Time Polymerase Chain Reaction  
RA      : Rheumatoid arthiritis 
RLR  : RIG-I like receptor 
RNA   : Ribonucleic Acid 
rpm   : Recolutions per minute 
SabA   : Sialic acid-binding adhesin 
SARM : Sterile alpha and HEAT/Armadillo motif 
sBAFF : Soluble BAFF 
sec   : Second 
SGECs : Salivary gland epithelial cells 
SHP-2  : Src homology 2 domain 
SLE   : Systemic lupus ertyhematosus 
STAT  : Signal Transducer and Activator of Transcription 
S/N  : Supernatant 
SS  : Sjögren’s Syndrome 
ssRNA : Single-standed RNA 
T1  : Transitional type 1 
T2   : Transitional type 2 
T4SS   : Type IV secretion system 
TACI  : Transmembrane activator and calcium modulator cyclophilin  
                          interacting ligand 
TAK1  : TGF-beta activated kinase-1 
TBK1   : TANK-binding kinase 1 
Th1     : T helper 1 
Th 17   : T hepler 17 
TIR   : Toll – IL-1 receptor 
TLR  : Toll-like receptor 
TRAF  : TNF receptor – associated factor 
TRAM : Toll-like receptor 4 adaptor protein 
TRIF  : TIR domain- containing adapter-inducing interferon-   
Tm   : Melting Temperature 
TNF   : Tumor necrosis factor 
TRAF  : Tumor necrosis factor receptor-associated factors 
TWEAK  : TNF- related weak inducer of apoptosis 
UV   : Ultraviolet 
V   : Volt 
Vac A  : Vacuolating cytotoxin A 
WCE  : Whole cell extract 
 
 
 
 xviii 
 
 
 
 
 
 
 
 
 xix 
 
LIST OF TABLES 
 
                  Page 
Table 2.1: Components of Helicobacter growth agar  .............................................. 19 
Table 2.2: Antibiotics used in Helicobacter agar  ..................................................... 19 
Table 2.3: 1000X Antibiotic Cocktail  ...................................................................... 20 
Table 2.4: 200X Antibiotic Cocktail  ........................................................................ 20 
Table 2.5: Solutions used for Helicobacter growth  ................................................. 20 
Table 2.6: Freezing medium of Helicobacter pylori  ................................................ 20 
Table 2.7: Solutions and media used in cell culture  ................................................. 21 
Table 2.8: Buffers and solutions used in cell culture  ............................................... 21 
Table 2.9: Buffers and solutions used in agarose gel electrophoresis  ...................... 21 
Table 2.10: Chemical list in this study  ..................................................................... 22 
Table 2.11: WCE components and amounts ............................................................. 23 
Table 2.12: Dilution scheme for BCA Assay Standards  .......................................... 24 
Table 2.13: Buffers, solutions and supplements used for Western Blotting ............. 24 
Table 2.14: Primers and sequences used for qRT-PCR  ........................................... 26 
Table 2.15: Antibodies and inhibitor used in this study  ........................................... 26 
Table 2.16: The equipment used in this study  .......................................................... 27 
Table 2.17: Commercial kits used in this study  ....................................................... 29 
Table 2.18: Reagents for cDNA synthesis  ............................................................... 34 
Table 2.19: cDNA PCR conditions  .......................................................................... 34 
Table 2.20: Reagents for PCR  .................................................................................. 35 
Table 2.21: Conventional PCR conditions  ............................................................... 35 
Table 2.22: Agarose gel preparation  ........................................................................ 36 
Table 2.23: qRT-PCR reagents  ................................................................................ 36 
Table 2.24: Real-time PCR conditions  ..................................................................... 37 
Table 2.25: Standards preparation for Human BAFF ELISA ................................... 39 
 
 
 
 
 
 xx 
 
 
 
 
 
 
 
 
 
 
 
 
 xxi 
 
LIST OF FIGURES 
 
 
                            Page 
 
Figure 1.1   : Helicobacter pylori virulence factors .................................................... 2 
Figure 1.2   : Helicobacter pylori virulence genes located on cagPAI  ...................... 3  
Figure 1.3   : Translocation of Cag A into host cell .................................................... 6  
Figure 1.4   : Various forms of BAFF and APRIL ..................................................... 8 
Figure 1.5   : Receptors of BAFF and APRIL ............................................................ 9  
Figure 1.6   : Toll-like receptors and ligands ............................................................ 12  
Figure 1.7   : Classification of NOD- like receptors according to their N- 
                       terminal domains        13 
Figure 1.8   : Structure of NOD1 .............................................................................. 14 
Figure 1.9   : NOD1 activation leads to IFN-  expression ...................................... 15 
Figure 1.10 : JAK/STAT signalling pathway ........................................................... 17 
Figure 3.1   : Treatment with H.pylori G27 WT sonicate leads to BAFF  
                       expression in KATO-III cells. ............................................................. 41 
Figure 3.2   : BAFF expression level is decreased in H.pylori G27 Cag A 
                       sonicate- treated KATO-III cells at 24h .............................................. 42 
Figure 3.3   : BAFF protein level is decreased in H.pylori G27 Cag A  
                       sonicate- treated KATO-III cells at 24h  ............................................. 43 
Figure 3.4   : BAFF secretion is induced in H.pylori G27 WT sonicate-  
                       treated KATO-III cell .......................................................................... 45 
Figure 3.5   : Treatment with H.pylori G27 WT sonicate leads to APRIL  
                       expression in KATO-III cells... ........................................................... 46 
Figure 3.6   : APRIL expression level is decreased in H.pylori G27 Cag A  
                       sonicate-   treated KATO-III cells at 24h ............................................ 47 
Figure 3.7   : APRIL protein level is decreased in H.pylori G27 ΔCag A  
                       sonicate- treated KATO-III cells at 24h. ............................................. 48 
Figure 3.8   : NOD1 expression is induced by H.pylori G27 WT sonicate- 
                       treated KATO-III cells at 24h  ............................................................ 50 
Figure 3.9   : NOD1 expression is increased in H.pylori G27 WT sonicate-  
                       treated KATO-III cells ........................................................................ 51 
Figure 3.10 : Treatment with H.pylori G27 WT sonicate induces IRF7  
                       expression in KATO-III cells .............................................................. 52  
Figure 3.11 : IRF7 expression is increased in H.pylori G27 WT sonicate-  
                       treated KATO-III cells ........................................................................ 55 
Figure 3.12 : H.pylori G27 WT sonicate induces IFN-  expression in  
                       KATO-III cells at 24 h  ....................................................................... 54 
Figure 3.13 : IFN- β expression level is decreased in H.pylori G27 Cag A       
                       sonicate- treated KATO-III cells at 24h .............................................. 55 
Figure 3.14 : Treatment with H.pylori G27 WT sonicate induces  
                       STAT1 phosphorylation  in KATO-III cells ....................................... 57 
 xxii 
Figure 3.15     : Treatment with JAKI inhibits BAFF expression in  
                           KATO-III cells. ............................................................................... 58  
Figure 3.16     : mBAFF and sBAFF protein levels were decreased in the  
                           presence of JAKI ............................................................................. 59 
Figure 3.17     : BAFF secretion levels were decreased in JAKI- treated 
                           KATO-III cells. ............................................................................... 61 
Figure 3.18     : Treatment with JAKI  inhibits APRIL expression in  
                           KATO-III cells ...............................................................................  62 
Figure 3.19     : APRIL protein levels were decreased in JAKI- treated  
                           KATO-III cells   .............................................................................. 63 
Figure 3.20     : JAKI inhibits NOD1 expression in KATO-III cells ........................ 64 
Figure 3.21     : IRF7 expression is decreased in JAKI- treated KATO-III cells ...... 65 
Figure 3.22     : IFN-  expression is decreased in JAKI- treated  
                          KATO-III cells ................................................................................. 66 
Figure 4.1       : Proposed model of BAFF and APRIL expression in H.pylori  
                           G27 sonicate- treated KATO-III cells ............................................. 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxiii 
 
INVESTIGATION OF BAFF EXPRESSION AND SIGNALING PATHWAY 
FROM HELICOBACTER-INFECTED GASTRIC EPITHELIAL CELLS ON 
MOLECULAR LEVEL 
SUMMARY 
 
Helicobacter pylori (H.pylori) is a gram negative, spiral –shaped, microaerophilic 
bacterium which colonize in the human stomach and is significantly associated with 
chronic gastritis, gastric adenocarcinoma, gastric ulcers and gastric lymphoma. In 
developing countries, 80% of the population is infected with Helicobacter pylori but 
most of them are asymptomatic. The bacterial virulence factors, host genetic traits, 
and environmental parameters are responsible for the Helicobacter-associated 
diseases. H.pylori-driven inflammation in stomach leads to follicular gastritis in 
childhood and MALT (mucosa-associated lymphoid tissue) lymphoma in adults, 
both of which are characterized by the presence of B cell follicles.  
To understand the contribution of H.pylori on gastric immunopathology formation 
indirectly through affecting gastric epithelial cells in molecular level, we focus on B 
cell activating factor (BAFF), which was shown to be produced in H. pylori-infected 
gastric epithelial cells. BAFF is a member of TNF (tumour necrosis factor) family 
and first identified in 1999. BAFF is also termed as BLys, THANK, TALL-1, 
zTNF4, TNFSF13B. BAFF is located on chromosome 13 in humans and has 6 exons. 
BAFF is responsible for regulation innate and adaptive immunity. It has a role on B 
cell maturation, proliferation, development and survival. BAFF is produced by many 
cell types including monocytes, neutrophils, dendritic cells, activated T cells, 
epithelial cells and macrophages. BAFF production is also reported from cancer 
cells. Elevated levels of BAFF were found in sera of several autoimmune diseases 
patients such as rheumatoid arthritis (RA), Sjögren’s syndrome (SS), experimental 
autoimmune encephalomyelitis (EAE), systemic lupus erythematosus (SLE). 
 
APRIL (a proliferation inducing ligand) is a homologue of BAFF and a member of 
TNF family cytokines. We also focus on H.pylori G27 WT sonicate- stimulated 
APRIL production from gastric epithelial cells. APRIL is also termed as TRDL-1, 
TALL-2 and TNFSF-13a. APRIL is located on chromosome 17 in humans and has 6 
exons. APRIL is expressed by monocytic, dendritic, epithelial cells, macrophages 
and cancer cells. APRIL has a role on plasma cell survival and stimulation of tumour 
cells. High levels of APRIL were also found in sera of autoimmune disease patients. 
In this study, the effect of H.pylori virulence factor Cag A (cytotoxin- associated 
gene-A) on BAFF & APRIL production from gastric epithelial cells and their 
signalling pathway were investigated. It was reported that H.pylori virulence factor 
Cag A is associated with development of gastric malignancies. For that reason, a 
gastric epithelial cell line KATO-III was treated with wild- type (WT) H. pylori G27 
strain sonicate and its ΔCag A mutant sonicate. The differences of BAFF expression 
in mRNA level were determined by quantitative real-time PCR (qRT-PCR). Our 
 xxiv 
research indicates that BAFF is produced from H.pylori G27 WT sonicate- treated 
KATO-III cells. It was observed that BAFF expression is significantly decreased 
from H.pylori G27 ΔCag A sonicate- treated KATO-III cells compared to H.pylori 
G27 sonicate- treated cells. This result suggests that H.pylori virulence factor Cag A 
has an effect on BAFF production in KATO-III cells. BAFF protein levels were 
detected by using Western Blotting and ELISA. BAFF protein levels were also 
significantly increased in H.pylori G27 WT sonicate- treated KATO-III cells 
compared to untreated controls and H.pylori ΔCagA mutant sonicates- treated 
KATO-III cells had less BAFF production compared to H.pylori wild-type 
counterpart. Findings revealed a correlation between RNA and protein levels of 
BAFF in response to H.pylori G27 WT sonicate.   
APRIL was found to be expressed less than BAFF. Findings suggest that APRIL 
expression is significantly increased in H.pylori G27 WT sonicate- treated KATO-III 
cells. qRT-PCR and Western Blotting results indicates that H.pylori virulence factor 
Cag A has a role in APRIL expression and production. 
NOD1 (nucleotide –binding oligomerization domain) is an intracellular pattern 
recognition receptor and is found in the cytoplasm. NOD1 is a member of NLRs and 
contains CARD (caspase recruitment domain domain). NOD1 is present in all    
gram – negative bacteria and some gram - positive bacteria. It recognizes peptide 
derived peptidoglycans (PGNs) derived from bacterial cell walls. It is reported that 
H.pylori PGNs induce NOD1 expression in intestinal epithelial cells. In our work, 
NOD1 is also found to be expressed by H.pylori sonicates- treated KATO-III cells. It 
was observed that NOD1 expression is increased in H.pylori G27 WT sonicate- 
treated cells compared to untreated controls. It is known that activation of NOD1 
leads to IFN-  (interferon-beta) expression via IRF7 translocation to nucleus. 
Secreted type I cytokine IFN- , binds to its own receptor on the cell surface and 
activates JAK/STAT signalling pathway. In the light of this knowledge, we 
investigated IRF7 expression and IFN-  expression levels in H.pylori sonicates- 
treated KATO-III cells by using qRT-PCR. qRT-PCR results suggest that IRF7 
expression level is increased in H.pylori G27 WT sonicate- treated KATO-III cells. 
Following IRF7 expression levels, IFN-  expression levels were also investigated by 
qRT- PCR. It was observed that IFN-  expression level was increased in H.pylori 
G27 WT sonicate- treated cells compared to untreated control.   
 
In literature, BAFF production is reported from different epithelial cells such as 
airway epithelial cells and salivary gland cells via JAK/STAT signalling pathway. 
We aimed to elucidate H.pylori G27 WT sonicate- stimulated BAFF signalling 
pathway in gastric epithelial cells. In order to investigate H.pylori G27 WT sonicate- 
induced JAK/STAT signalling pathway, KATO-III cells were treated with different 
doses of JAKI and then stimulated with H.pylori G27 WT sonicate for 24 h. 
According to Western Blotting results, STAT1 phosphorylation levels were 
decreased in the presence of JAKI in a dose –dependent manner of JAKI. Our results 
suggest that JAK/STAT signalling pathway plays a role in BAFF&APRIL 
expression and secretion in H.pylori G27 WT sonicate- treated KATO-III cells. 
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HELİKOBAKTER – İNFEKTE MİDE EPİTEL HÜCRELERİNDEN BAFF     
           ÜRETİMİNİN VE SİNYAL YOLAĞININ MOLEKÜLER  
                                    DÜZEYDE ARAŞTIRILMASI 
                                                          ÖZET 
Helikobakter pilori (H.pilori) gram –negatif, spiral şekilli, mikroaerofilik bir bakteri 
olup insan midesinde kolonize olmakla beraber kronik gastrit, gastrit 
adenokarsinoma , ülcer ve  gastik lenfomayla yakından ilişkili olan bir bakteridir. 
Gelişmekte olan ülkelerin %80’i Helikobakter pilori ile infektedir fakat bireylerin 
çoğu asemptomatiktir. Bakteri virülans faktörleri, konağın genetik özellikleri ve 
çevresel etkenler Helikobakter ile ilişkili hastalıklardın gelişmesinden sorumludur. 
H. pilori kaynaklı mide enflamasyonu çocuklarda foliküler gastrite, yetişkinlerde ise 
MALT(mukoza ilişkili lenfoid doku) lenfomaya sebep olmaktadır. Bu iki hastalık da 
B hücre folikülleri varlığı ile karakterizedir.  
 
H. pilori’nin mide epitel hücrelerini etkileyerek gastrik immunopatoloji oluşumunda 
katkısını anlayabilmek amacıyla, araştırmamızda H. pilori ile enfekte mide epitel 
hücreleri tarafından üretildiği gösterilen B hücre aktive edici sitokin (BAFF) 
üzerinde yoğunlaşmaktayız. TNF (tümör nekrozis faktör) ailesi üyelerinden olan 
BAFF ilk olarak 1999’da keşfedilmiş olup, BLys, THANK, TALL-1, zTNF4, 
TNFSF13B adları ile de anılmakadır. BAFF, insanlarda 13. kromozomun uzun 
kolunda kodlanmakta ve 6 adet ekzonu bulunmaktadır. BAFF, doğustan ve sonradan 
kazılan bağışıklıkta regüle edici özelliği bulunan bir sitokindir. Aynı zamanda B 
hücre matürasyonu, proliferasyonunda, yaşamı, geşilmesi, farklılaşmasında görev 
alan bir sitokindir. BAFF çeşitli hücrelerce üretilmektedir. Örneğin monositler, 
nötrofiller, dendritik hücreler, aktive olan T hücreleri, epitel hücreler, makrofajlar 
tarafından üretildikleri gösterilmiştir. BAFF’ın aynı zamanda kanser hücrelerinden 
de üretildiğini gösteren çalışmalar vardır. Romatoid artrit (RA), Sjögren sendromu 
(SS), multiple skleroz (MS), deneysel otoimmün ensefalomiyelitis (EAE) ve sistemik 
lupus eritamatozus (SLE) gibi otoimmün hastaların serumlarında yüksek düzeyde 
BAFF saptanmıştır. 
 
APRIL (proliferasyon indükleyici ligand), BAFF’ın homoloğu olan ve yine TNF 
ailesine ait bir sitokindir. Çalışmalarımız H.pilori G27 WT sonikatı ile stimule edilen 
gastrik epitel hücrelerinden APRIL ekspresyonu ve üretimi ile devam etmiştir.  
APRIL, TRDL-1, TALL-2 and TNFSF-13a gibi isimlerle de terimlendirilir. 
Ġnsanlarda 17. kromozomun küçük kolunda yer alıp , 6 ekzona sahiptir. APRIL da 
monositik, dendritik, epitel , makrofaj ve çeşitli kanser hücrelerince üretilmektedir. 
APRIL’ın plasma B hücrelerinin proliferasyonunu ve daha çok tümor hücrelerini 
stimüle edici özelliği olduğu literatürde gösterilmiştir. APRIL’ın da yüksek düzeyde 
otoimmün hastaların serumlarında bulunduğu gösterilmiştir.  
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Bu çalışmamızda H.pilori virulans faktörlerinden Cag A (sitotoksin- ilişkili gen A) 
virulans faktörünün gastik epitel hücrelerinden BAFF ve APRIL üretimine etkisi ve 
sinyal yolakları araştırılmıştır. Cag A, H.pilori’nin en önemli virulans faktörlerinden 
biri olup gastrik hastalıklarının gelişmesinde önemli rol oynadığı gösterilmiştir.    
Bu amaçla mide epitel hücresi olan KATO-III, yabanıl (WT) H.pilori G27 suşu ve 
onun ΔCag A (Cag A virulans faktörü bulunmayan) mutantı ile muamele edilmiştir. 
mRNA seviyelerindeki BAFF ekspresyon farkları kantitatif- gerçek zamanlı PZR ile 
tayin edildi. Elde edilen bulgular H.pilori G27 WT sonikatının incelenen KATO-III 
hücre hattında BAFF üretimine sebep olduğunu göstermektedir. H.pilori G27 ΔCag 
A mutantı sonikatı ile muamele edilmiş KATO-III hücrelerindeki BAFF 
ekspresyonu, H.pilori G27 WT sonikatı ile muamele edilmiş hücrelere göre daha 
düşük seviyelerde bulunmuştur. Bu sonuç bize Cag A virulans faktörünün BAFF 
üretimi üzerindeki etkisini göstermektedir. Protein düzeyinde yapılan Western 
Blotlama ve BAFF ELIZA çalışmalarının sonuçları gösterdi ki, BAFF üretimi H. 
pilori G27 WT ile muamele edilmiş hücrelerde daha fazla saptanmıştır. RNA ve 
protein düzeyindeki  çalışmalar birbirini tamamlamaktadır.  
APRIL eksresyonu da BAFF kadar yüksek düzeylerde olmasa da H.pilori G27 WT 
ile muamele edilen KATO-III hücrelerinde APRIL ekspresyonu daha fazla miktarda 
gözlenmiştir. Protein düzeyindeki Western Blotlama çalışmalarına göre de APRIL 
üretiminde Cag A virulans faktörünün önemli rol oynadığı gösterilmiştir.  
NOD1 (nükleotid bağlayıcı oligomerizasyon domain proteini 1), sitoplazmada 
bulunan bir hücre içi patojen tanıma reseptörü olup NLR (NOD-benzeri reseptör) 
ailesinin CARD bölegesi taşıyan bir üyesidir. Genellikle tüm gram-negatif ve bazı 
gram-pozitif bakterilerde bulunup, hücre duvarından kökenlenen peptidoglikanları 
tanımakla görevlidir. Helikobakter pilori’den kökenlenen peptidoglikanların NOD1 
ekspresyonunu arttırtığı daha önce bağırsak epitel hücrelerinden gösterilmiştir. Bizim 
çalışmamızda da H.pilori G27 WT sonikatı ile muamele edilmiş mide epithel 
hücrelerinden üretilen NOD1 ekspresyonu ekspresyonu gerçek zamanlı PZR tekniği 
kullanılarak analiz edilmiştir. NOD1 ekspresyon sonuçlarına göre H.pilori G27 WT 
sonikatı ile muamele edilen hücreler, H.pylori sonikatı ile muamele edilmeyen 
hücrelere göre daha fazla NOD1 ekspres etmektedirler. Literatürde NOD1’ın IRF7 
(interferon regülator faktör 7) ’nin nukleusa translokasyonunu sağlayarak IFN-  
(Ġnterferon-beta) eksprese edilemesine yol açtığı bilinmektedir. Üretilen tip-I sitokin 
olan IFN-  ’nın da hücre yüzeyinde bulunan Ġnterferon-beta reseptörüne bağlanıp 
JAK/STAT yolağını aktive edici özelliği vardır. Bu bilgiler ışığında, bizim 
çalışmalarımızda H.pilori sonikatı ile muamele edilmiş KATO-III hücrelerinden  
IRF7’nin ve IFN- ’nın ekpresyonlarını kantitatif- gerçek zamanlı PZR tekniği 
kullanılarak araştırılmıştır. Kantitatif- gerçek zamanlı PZR sonuçlarına göre, H.pilori 
G27 WT sonikatı muamele edilen hücrelerdeki IRF7’nin ekspresyonudaki artışın 
H.pilori sonikatı ile muamele edilmeyen hücrelere göre fazla olduğu gözlenmiştir. 
IRF7 ekspresyon sonuçlarını takiben H.pilori G27 WT sonikatı ile muamele edilmiş 
hücrelerden IFN-  sitokinin ekpresyon düzeyindeki analizleride kantitatif- gerçek 
zamanlı PZR ile araştırılmıştır. Elde edilen bulgulara göre, H.pilori G27 WT sonikatı 
varlığında IFN- ’nın üretiminin H.pilori sonikatı ile muamele edilmeyen KATO-III 
hücrelerine göre daha fazla ekprese edildiği gösterilmiştir.  
Literatürde hava yolu aracılı epitel ve tükürük bezi epitel hücrelerinden BAFF 
üretiminin JAK/STAT (Janus tirozin kinaz /sinyal ileticisi ve transkripsiyon 
aktivitörü) aktive edici yolağı aracılı ile olduğu gösterilmiştir. Çalışmamızda H.pilori 
G27 WT sonikatı ile infekte mide epitel hücrelerinde ki BAFF üretim yolağının 
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aydınlatılması amaçlanmıştır. Bu amaçla H.pilori G27 WT sonikatı ile indüklenen 
hücrelerden JAK/STAT sinyal yolağını aydınlatmak için KATO-III hücreleri çeşitli 
dozlarda JAKI (JAK inhibitörü) ile muamele edilip ardıdan H.pilori G27 WT 
sonikatı ile stimule edilmiştir. Elde edilen Western Blotlama sonuçlarına göre JAKI 
kullanıldığında STAT1’ in fosforilasyonundaki azalma gösterilmiştir. BAFF ve 
APRIL ekspresyonu ve üretimide JAKI kullanıldığında azalmaktadır. BAFF ve 
APRIL üretiminde JAK/STAT sinyal yolağının mide epitel hücrelerinde de rol 
oynadığını göstermiştir.  
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1. INTRODUCTION 
1.1 Helicobacter pylori 
Helicobacter pylori (H.pylori) is a gram-negative, spiral-shaped, microaerophilic, 
flagellate bacterium that can successfully colonizes the human stomach. More than 
50% of the world population is infected with H.pylori but most of the infected 
individuals are asymptomatic [1]. In early childhood, infection can be passed through 
gastric - oral route within families and can be established as a long- term infection if 
not treated. Also host’s genetical backgrounds, environmental factors, virulence 
factors of Helicobacter strains are important in the adaptation of this bacterium to the 
host stomach. Helicobacter pylori was first identified by two Australian scientists 
Dr. Barry Marshall and Dr. Robin Wallen in 1982. In 1994, H.pylori has been 
classified as class I carcinogen bacterium by the International Agency for Research 
on Cancer and reported as the main factor for developing gastric cancer [2]. The 
discovery of H.pylori and its relation to the gastric malignancies won the Nobel Prize 
in Medicine in 2005.  
All Helicobacter pylori strains possess urease, catalase and oxidase enzymes. Urease 
facilitates neutralization of the gastric acidic environment so that H.pylori can 
survive in human stomach. Urease also plays a role in degradation of urea into 
ammonia and this ammonia is used for amino acid biosynthesis. Oxidase protects 
bacteria against free- radicals. Catalase enzyme is required for the growth and 
survival of H.pylori and also protects bacteria against hydrogen peroxide.  
Infection with Helicobacter pylori is associated with the development of chronic 
gastritis, peptic ulcers, duodenal ulcers, gastric adenocarcinoma, and mucosa-
associated lymphoid tissue lymphoma (MALT) [3]. Gastric adenocarcinoma was 
listed as a second cause of cancer-associated death in world - wide [4]. It was shown 
that Helicobacter – specific virulence genes are important in the progression of 
gastric malignancies [5]. 
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1.2 Helicobacter pylori Virulence Factors 
Most of the Helicobacter pylori-infected patients do not develop any gastric 
complications. This situation led to notion that some H.pylori strains may be more 
virulent than others. Adhesion molecules are responsible for the adherence of 
bacteria to host cells. Also, these molecules are required for H.pylori colonization in 
human stomach (Figure 1.1). H.pylori adherence molecules are members of outer 
membrane protein (OMP) family and named as Hop family. Hop family contains 
BabA (blood group antigen binding adhesion), OipA (the outer inflammatory protein 
A), SabA (sialic acid-binding adhesion), HopZ and AlpA/B [7]. Apart from H.pylori 
virulence factors and adhesion molecules, flagella, LPS (lipopolysaccharides), 
peptidoglycan (PGN), superoxide dismutase, catalase, and protease enzymes of 
H.pylori may play a role in severity of diseases. 
Several H.pylori virulence factors have been identified and found that some of these 
factors play an important role in developing gastric malignancies. Most of these 
virulence factors are located in the cag Pathogenicity Island (cagPAI). Another 
important H.pylori virulence factor is VacA (vacuolating cytotoxin A). VacA 
augments the risk factor for developing gastric cancer [6] (Figure 1.1).  
 
Figure 1.1 : Helicobacter pylori virulence factors (adapted from ref. 6) 
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1.2.1 The H.pylori cag Pathogenicity island  
The cag Pathogenicity Island (cagPAI) was first identified in 1996. cagPAI is a 40 kb 
DNA  insertion element and includes approximately 31 genes. cagPAI is present in 
60-70% of Western H.pylori strains and approximately 100% of East –Asian 
H.pylori strains [8]. This island encodes a type IV secretion system (T4SS). T4SS 
also exists in other bacteria such as Agrobacterium, Legionella, Bartorella and 
Bordetella. T4SS is required for bacterial conjugation and translocation of bacterial 
effector proteins into the host gastric epithelial cells [9,10]. Helicobacter pylori uses 
T4SS injection apparatus for translocation of Cag A protein and peptidoglycans 
(PGNs) into the host cell [11]. 
CagPAI contains several virulence factors such as Cag A, Cag E, Cag L, Cag Y, and 
Cag I [12] (Figure 1.2). 
 
       Figure 1.2 : Helicobacter pylori virulence genes located on cagPAI (adapted   
                           from ref.12)      
1.2.1.1 Cag A virulence factor 
The most important H.pylori virulence factor Cag A is encoded by the cytotoxin- 
associated gene A and localized in the pathogenicity island. Cag A is a highly 
immunogenic, 120-140 kDa protein. Cag A protein is closely associated with the 
severe gastric diseases such as peptic ulcers and gastric cancer. H.pylori strains have 
been divided in two types as type I and type II [13]. Type I strains possess Cag A and 
Vac A, and they are important for the development of gastric malignancies. Type II 
strains lack these virulence factors. Cag A oncoprotein has repeated sequences 
located in 3’ region. These repeated regions consist of Glutamine- Proline-
Isoleucine- Tyrosine- Alanine (EPIYA) motifs and these motifs include a tyrosine 
phosphorylation site. There are four different EPIYA segments: EPIYA-A, EPIYA-
B, EPIYA-C and EPIYA-D. Cag A from Western H.pylori isolates have EPIYA-A, 
EPIYA-B and EPIYA-C (EPIYA-ABC type) whereas CagA from East Asian 
H.pylori isolates possess EPIYA-A, EPIYA-B and EPIYA-D (EPIYA-ABD type) 
[14]. EPIYA-D motif is unique for East Asian Cag A and is associated with the 
gastrointestinal diseases.  
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1.2.1.2 Other virulence factors in cagPAI 
One of the other H.pylori effector protein is Cag E (cytotoxin- associated gene-E) 
which is conserved among strains. Cag E is located in the right half of the cagPAI 
and helps the translocation and phosphorylation of Cag A protein. Cag E also has a 
role in induction of proinflammatory cytokines such as IL-8 (Interleukin-8) 
(neutrophil-activating chemokine). IL-8 secretion is mediated by NF- B (Nuclear 
Factor -kappa B) pathway [15]. 
Cag L is located at the surface of the pilus and this virulence factor has a specific 
Arginine-Glycine-Aspartate (RGD) motif. This motif is recognized by the 5 1 
integrin receptor on the target epithelial cell. CagL helps translocation of Cag A 
protein into the cytoplasm of host cell [16]. Also, CagL activates host Src and host 
focal adhesion kinase (FAK) for phosphorylation of Cag A protein. 
Cag Y virulence factor is found at the pilus and both Cag Y and Cag I are required 
for Cag A translocation. 
1.2.2 Vac A (vacuolating cytotoxin A) virulence factor 
Vac A is an important key toxin of H.pylori. Beside Cag A, H.pylori virulence factor 
Vac A protein also leads to gastric malignancies. H.pylori strains which possess cag 
A and Vac A are associated related with development of gastric cancer [5]. Among 
all H.pylori strains possess vac A gene and there is no close homologous of this 
virulent factor in other Helicobacter species or other bacteria. Vac A has several 
functions including vacuole formation and membrane channel formation in epithelial 
cell. Vac A initiates apoptotic cascade by inducing cytochrome c release from 
mitochondria via increasing expression of a pro-apoptotic protein Bax, and 
decreasing expression of an anti-apoptotic protein Bcl2 which in turn disrupts 
mitochondrial functions. Inhibition of T cell proliferation is maintained by Vac A 
through inactivation of transcription factor NFAT (nuclear factor of activated T 
cells), and blockage of IL-2 secretion. IL-2 is an important cytokine for T cell 
activation and survival [17, 18]. 
 Vac A has allelic variations in signal (s), intermediate (i) and middle (m) regions. s 
regions has s1 and s2 alleles, and s1 allele is more related with an increased  risk for 
peptic ulceration and gastric cancer than s2 [19]. Almost all Cag A positive strains 
contain s1 allele and Cag A negative strains possess s2/m2. The i and the m regions 
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also have i1 and i2, m1 and m2 alleles respectively. Vac A s1/m1 strains are more 
virulent than s2/m2 strains [20]. vacA gene encodes 140 kDa pro-toxin protein and 
has three components: a signal sequence, a passenger domain and an auto-transporter 
domain. Signal sequence helps the translocation of pro-toxin. The passenger domain 
contains two subunits p33 and p53 respectively. p33 subunit has a role in the pore 
formation, cell binding and initiation of apoptosis via going to mitochondria. p53 
subunit has a role in the cell binding, anionic membrane channels and vacuole 
formation  [21,22,23,24]. 
1.2 Cag A Translocation via Type IV Secretion System 
Cell membrane- attached H.pylori injects Cag A protein into host cell. Once Cag A is 
translocated into host cell it localizes at the inner surface of the plasma membrane 
and then undergoes tyrosine phosphorylation at EPIYA motifs by the host Src and 
Abl kinases. Src family kinases are c-Src, Lyn, Fyn, and Yes. These kinases are 
expressed by gastric epithelial cells. These kinases are required for Cag A 
phosphorylation and important for CagA-SHP2 complex formation. After 
phosphorylation of Cag A, SHP-2 (Src homology 2 domain - containing 
phosphatase) binds to tyrosine phosphorylated EPIYA motifs: EPIYA-C and 
EPIYA-D. Cag A positive strains which possess EPIYA-D binds stronger to SHP-2 
than EPIYA-C segment containing ones. SHP-2 kinase has a role in the transmission 
of signals and cell motility. Activation of SHP-2, dephosphorylates host cell proteins 
and leads to cellular morphological changes such as humming bird phenotype (more 
motile phenotype leading to cell scattering), cell elongation, apoptosis, spreading, 
migration of cells, disruption the cytoskeleton, epithelial cell functions, cell polarity 
and tight junctions [11,25,26,27] (Figure 1.3). 
Phosphorylated form of Cag A may also bind to C-terminal Src kinase (Csk) by SH2 
domain. Formation of CagA- Csk complex phosphorylates Src family kinases, down-
regulates CagA-SHP2 domain complex formation, inhibits c-Src activity and reduce 
phosphorylation levels of Cag A. This negative feedback signalling pathway leads to 
morphological changes in epithelial cells, cytoskeletal change, cell elongation and 
cellular rearrangements via tyrosine dephosphorylation of some proteins such as 
actin-binding proteins cortactin, ezrin and vinculin. Csk and SHP-2 compete with 
each other to bind tyrosine phosphorylated [28,29,30].  
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                   Figure 1.3 : Translocation of Cag A into host cell (adapted from ref. 27) 
1.3 B Cell Activating Factor (BAFF) 
BAFF, which is a short name of B cell activating factor, belongs to Tumor Necrosis 
Factor (TNF) super family. BAFF is identified in 1999 and also known as BLys, 
THANK, TALL-1, zTNF4, TNFSF13B. BAFF is located on chromosome 13q34 in 
humans and has six exons [31,32]. BAFF is an important cytokine for regulating 
innate and adaptive immunity. Like other TNF family ligands BAFF regulates 
lymphocyte functions, development of lymphocyte organs and immune tolerance. 
BAFF is a vital cytokine for B cells. This cytokine plays an important role in 
homeostasis of B cells, B cell maturation, B cell survival, B cell differentiation and 
development, plasma cell survival, antibody response promotion, Ig class switch 
recombination. It was demonstrated that BAFF deficient mice have failed to convert 
transitional type 1 (T1) B cells to transitional type 2 (T2) B cells [33,34,35,36].  
BAFF is expressed by various cell types such as monocytes, neutrophils, dendritic 
cells, activated T cells, epithelial cells, salivary gland cells, myeloid cells, 
macrophages and also by cancer cells such as B-CLL, Non Hodgkin’s lymphoma 
(NHL) and multiple myeloma (MM). In humans, high production of BAFF promotes 
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the survival of autoreactive B cells that leads to autoimmune diseases. Autoreactive 
B cells also produce BAFF and this cytokine acts as an autocrine survival factor for 
malignant B cells. Elevated levels of BAFF have been found in sera of autoimmune 
diseases patients such as rheumatoid arthritis (RA), Sjögren’s syndrome (SS), 
experimental autoimmune encephalomyelitis (EAE), systemic lupus erythematosus 
(SLE) and autoimmune thyroid disease [37,38,39,40]. 
Like other TNF family ligands, BAFF (285 amino acid protein) is a member of 
transmembrane II proteins and it shares 75 % homology with mice. It is initially 
synthesized as membrane-bound monomers and then can be oligomerized as trimers. 
Trimer oligomerization of BAFF leads to formation of virus like assembly. This 
homotrimeric structure of BAFF is required for receptor binding. BAFF can be also 
secreted as soluble form after cleavage from the cell surface by furin convertase. 
Souble BAFF (sBAFF) can be self –oligomerized and form a 20-mer and also can be 
found like trimer and 60- mer form [36,41]. 
An alternatively spliced form exon 3 of BAFF have been discovered in humans and 
named as BAFF (delta BAFF). BAFF (lacks 57 bp) can only exist as a membrane-
bound form and it can form a heterodimer with full length BAFF. A variant form of 
BAFF inhibits BAFF activity, and reduces BAFF release [41,42]. 
1.5 A Proliferation Inducing Ligand (APRIL)  
APRIL is a sister molecule of BAFF and classified in TNF family. It shares 50% 
homology with BAFF. APRIL is also termed as TRDL-1, TALL-2 and TNFSF-13a. 
It is found in chromosome 17p13.1 in humans and has six exons. APRIL is produced 
by dendritic cells, monocytes, macrophages, T cells and epithelial cells. Different 
tumour cells like gastrointestinal, duodenum, rectum, colon and stomach also express 
APRIL. High levels of APRIL were also reported in the sera of autoimmune patients 
[36,43,44]. 
Unlike BAFF, APRIL is cleaved in the Golgi apparatus by a furin- convertase and is 
able to perform its function as soluble form. Secreted APRIL cannot form a multimer 
virus-like cluster. Alternatively spliced form of APRIL, which is called APRIL, can 
also exist as membrane-bound. APRIL lacks a furin cleavage site. APRIL can make 
a fusion protein with another TNF family ligand TWEAK (TNF- related weak 
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inducer of apoptosis, TNFSF12) called TWE-PRIL also be found on the cell surface 
(Figure 1.4). Heterodimer of BAFF and APRIL have been reported just once in 
autoimmune diseases [41,45,46].  
 
               Figure 1.4 : Various forms of BAFF and APRIL (adapted from ref. 41) 
APRIL plays a role in the development and expansion of B cells. It also stimulates 
tumour cells growth. APRIL binds CD95 and induces apoptosis of tumour cells. 
[47]. It has been reported that this TNF family ligand has a role in the long-term 
survival of plasma cells in the bone marrow [36,48]. 
1.6 Receptors of BAFF & APRIL 
BAFF and APRIL are ligands for TNF family receptors. These receptors can be 
associated with TRAFs (TNF receptor associated factors) that have an inducible 
effect on survival, differentiation and function of B cells. BAFF and APRIL can both 
bind B cell maturation antigen (BCMA, TNFRSF17) and the transmembrane 
activator and calcium modulator cyclophilin interacting ligand (TACI, TNFRSF13b). 
APRIL have a high affinity to bind to BCMA than BAFF. BAFF can also 
specifically bind to BAFF receptor (BR3) which APRIL can not bind [49]. BR3 is 
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located on the human chromosome 22q13.2 and expressed by memory and naive B 
cells. BCMA is discovered on chromosome 16p13.1 in humans and is an important 
receptor for long-lived plasma cells. Third receptor TACI is found mainly on short-
lived plasma cells and located on 17p11.2 human chromosome. BCMA receptor 
contains a single cysteine- rich domain (CRD) whereas TACI receptor has two. BR3 
receptor has no CRD, but it is comprised of a typical module [40,49]. 
After cleavage from the cell membrane, soluble homotrimer form of BAFF can bind 
to its specific BR3 (TNFRSF13c) receptor. Soluble 60-mer form of BAFF can bind 
to TACI receptor whereas homotrimers of BAFF cannot activate TACI receptor. 
Only multimerized - membrane BAFF and multimerized APRIL can bind to TACI 
receptor. Beside BCMA and TACI receptors, APRIL can bind heparan sulphated 
proteoglycans (major component of extracellular matrix) on the cell surface of B 
cells. Heparan sulphated proteoglycans (HSPG) are known as receptors for APRIL. 
Heterodimer of BAFF and APRIL share receptors with APRIL such as TACI and 
BCMA [50] (Figure 1.5). 
 
Figure 1.5 : Receptors of BAFF and APRIL (adapted from ref. 50) 
These BAFF/APRIL receptors are expressed during different time points of B cell 
differentiation. BR3 is essential for survival and maturation of immature B cells. 
BR3 is expressed by Marginal zone (MZ) B cells and T cells. It has been shown that 
BR3 - deficient mice lacks mature B cells [40,51]. TACI receptor is also detected in 
MZ-B cells, B1-B cells and memory B cells. This receptor is required for the T – cell 
independent responses and known to suppress B cell proliferation and survival. 
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BCMA receptor expression was found in plasma cells.  
BAFF or APRIL activates NF- B and MAPK (Mitogen-activated protein kinase) 
pathways through binding to TACI and BCMA receptors. These receptors interact 
with death domain- containing proteins (TRAFs) which activates these pathways. 
This interaction leads to apoptotic or survival signals. BCMA receptor induction can 
also leads to activation of p38 MAPK and JNK (c-Jun N terminal kinase). TACI 
receptor induction can induce transcription factors AP-1 (activator protein-1) and 
NF-AT (nuclear factor of activated T cells), which are important proteins for 
lymphocyte survival [52]. 
1.7 Innate Immunity 
Innate immunity is the first line of defence against microorganisms in a non-specific 
manner. Pathogens can be recognized by host cell and destroyed in few minutes or 
hours. It serves as an immediate response to pathogens. Innate immunity is an 
evolutionary conserved defence system that is found in insects, fungi, plants and 
vertebrates.  
Monocytes, neutrophils, eosinophils, basophils, natural killer cells, and epithelial 
barriers are components of innate immunity. According to Charles A. Janeway 
theory, pathogens or pathogen derived components termed pathogen-associated 
molecular patterns (PAMPs) and molecules released by injured and dying cells 
termed as danger –associated molecular patterns (DAMPs) are recognized 
specifically by the immune system via pattern –recognition receptors (PRRs) or the 
other name is germ line- encoded receptors and activate innate immune cells [53]. 
These recognitions and activation of immune cells results in secretion of cytokines or 
chemokines and starts inflammatory responses. PRRs are essential receptors for the 
innate immunity. They are expressed by immune cells such as macrophages, 
dendritic cells, antigen - presenting cells (APCs), and by non- immune cells 
including epithelial cells. PRRs are divided in four families: Toll-like receptors 
(TLRs), NOD-like receptors (NLRs), C-type lectin receptors (CLRs) and RIG-I like 
receptors (RLRs). TLRs can be found either on the cell surface or endosomal 
compartments. NLRs are cytoplasmic receptors and they recognize intracellular 
pathogens or pathogen–derived components [54]. CLRs recognize bacterial and 
fungal components whereas RLRs recognize viral double-stranded RNA (dsRNA). 
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1.7.1 Toll-like Receptors 
Toll receptor was first identified in Drosophila melanogaster by Christiane Nüsslein-
Volhard in 1985 [55]. Toll was found as an essential receptor for fungal infection in 
Drosophila. After the discovery of Toll, its homologue Toll like-receptor (TLR4) 
was identified in mammals. Toll-like receptors (TLRs) are important sensors of 
innate immune system and these receptors can be activated via PAMPs and DAMPs. 
They are common in various species and expressed by immune and non-immune 
cells. They recognize pathogens or particles of pathogens and activate immune cell 
response. 13 TLRs have been identified in mammals. TLR 1 to 9 was conserved in 
human and mouse, but only mice express TLRs 11,12 and 13 [56]. Cytoplasmic 
domain of Toll resembles IL-1 receptor so it’s named as TIR (Toll-IL-1 receptor) 
domain. TIR domain mediates intracellular signalling. TLRs have leucine- rich 
repeats, which are required for ligand binding. There are 5 TIR adaptor molecules 
that play a role in signalling pathway: MyD88 (myeloid differentiation primary 
response gene -88), Mal (MyD88-adapter -like), TRIF (TIR domain- containing 
adapter-inducing interferon- ), TRAM (Toll-like receptor 4 adaptor protein), and 
SARM (sterile alpha and HEAT/Armadillo motif). These adaptor proteins activate 
kinases and induce the secretion of cytokines by NF- B and MAPK pathways. TLR 
stimulation also leads to activation of JAK/STAT signalling pathway, which is 
important in cytokine secretion [57]. 
TLRs recognize different microbial components. TLR1 recognizes peptidoglycan 
and lipoproteins in the interaction with TLR2. TLR2 can recognize 
lipoproteins/lipopeptides from different pathogens, peptidoglycan and lipoteichoic 
acid from gram-positive bacteria. TLR3 recognize double-stranded RNA (Figure 
1.6).  
TLR4 is required for LPS recognition. Bacterial flagella are recognized by TLR5 
receptor. TLR7 and TLR8 recognize single-stranded RNA (ssRNA) and nucleic acid 
structure of viruses. TLR9 is a critical receptor for CpG oligodeoxynucleotide (a 
synthetic DNA oligonucleotide in which a guanine is preceded by a cytosine 
nucleotide) recognition [58]. 
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Some of these TLRs such as TLR1, TLR2 and TLR4 are expressed on the cell 
membrane and some of them like TLR3, TLR7, TLR8 and TLR9 are localized in 
intracellular compartments such as endosomes [59] (Figure 1.6). 
 
                       Figure 1.6 : Toll-like receptors and ligands (adapted from ref. 59) 
1.7.2 NOD-like Receptors 
NOD-like receptors (NLRs) are intracellular sensors of PAMPs and DAMPs. They 
also play a key role in regulation of innate immunity. NLRs are expressed by 
immune cells such as lymphocytes, macrophages, dendritic cells and non-immune 
cells like epithelial cells. They are strongly conserved during evolution. Homologues 
of mammalian NLRs are discovered in plants and zebra fishes [60]. 22 members of 
NLRs exist in humans. NLRs consist of three domains: N-terminal domain (CARD, 
PYD, BIRs or AD) which is required for homophilic protein-protein interaction, a 
central NOD (NACHT or NBD) domain which is common to all NLRs and it 
facilitates self oligomerization, and C-terminal leucine-rich repeat (LRR) which is 
essential for ligand recognition. 
NLRs are divided in four groups according to their N-terminal domains. First family, 
NLRA have an acidic transactivation domain: CIITA (class II, major 
histocompatibility complex, transactivator). NLRB family contains BIR (baculoviral 
inhibitor of apoptosis repeat) domain: NAIP. NLRC families contain CARD (a 
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caspase recruitment domain): NOD1, NOD2, NLRC3, NLRC4, NLRC5. NLRP 
subgroup has a pyrin domain (PYD): NLRP1-14. CARD and PYD containing 
proteins are involved in apoptosis and inflammatory processes [61]. The last group is 
NLRX, which is newly discovered dsRNA receptor and have no homology to other 
N-terminal domain of NLRs (Figure 1.7).  
 
 
 
Figure 1.7 : Classification of NOD- like receptors according to their N-terminal   
                   domains (adapted from  ref.61) 
1.7.2.1 NOD1 
Helicobacter infection induces adaptive Th1 (T helper 1) and Th17 (T helper 17) 
immune responses, which are important for the protective immune response against 
H.pylori. Apart from the adaptive immunity, innate immunity also becomes activated 
by H.pylori infection in gastric epithelial cells. Nucleotide-binding oligomerization 
domain - containing protein 1 (NOD1) is an important component of innate 
immunity. NOD1 is a well - known member of NLR family. NOD1 is a mammalian 
protein that is expressed in the cytosol and recognizes the peptides derived from 
peptidoglycan (PGN) of bacterial cell wall and stimulate immune response. NOD1 is 
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expressed by gastrointestinal epithelial cells, primary epithelial cells, and antigen -
presenting cells. Another well described NLR family member NOD2 is expressed in 
specialized epithelial cells such as Paneth cells. -d-glutamyl-meso-diaminopimelic 
acid (iE-DAP) containing bacterial molecules are ligands for NOD1 whereas 
muramyl di-peptide (MDP) can recognized by NOD2. All bacteria possess MDP but 
only some gram-positive and almost all gram-negative bacteria have iE-DAP [62]. It 
was demonstrated that H.pylori infected gastritis patients have higher NOD1 
expression compared to non-infected patients or H.pylori non –associated gastric 
patients [63]. Activation of NOD1 and NOD2 both promote secretion of pro-
inflammatory cytokines. 
NOD1 consist of three domains; N-terminal CARD, a central NOD and                    
C-terminal leucine rich domain (LRR) [63,64] (Figure 1.8). 
 
Figure 1. 8 : Structure of NOD1 (adapted from ref. 63) 
Helicobacter pylori- derived peptidoglycan can enter to the host cell via T4SS and 
induce activation of NF- B pathway and IL-8 secretion. In the absence of T4SS, the 
infection with H.pylori can still deliver its peptidoglycan and cause inflammation. It 
has been reported that H. pylori OMVs containing peptidoglycan can enter the cell 
through specialized domains of cell membranes called lipid rafts. H.pylori 
peptidoglycans bind to LRR domain of NOD1 and molecule (NOD1) undergoes 
conformational change [65]. CARD domain of NOD1 and CARD domain of 
downstream molecule serine/threonine kinase RICK have an interaction with each 
other. This interaction leads to ubiquitination of RICK, which promotes binding and 
activation of TAK1 (TGF-beta activated kinase-1). TAK1 inhibits the NF- B 
pathway by degradation of IkBa complex. Activated RICK binds to TNF receptor-
associated factor 3 (TRAF3). Interaction between RICK and TRAF3 leads to 
activation of TANK-binding kinase 1 (TBK1) and induction of Interferon regulatory 
factor 7 (IRF7). Translocation of IRF7 into nucleus initiates IFN-  expression from 
host cell (Figure 1.9). 
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Figure 1.9 : NOD1 activation leads to IFN-  secretion (adapted from ref. 62) 
Secreted IFN-β induces expression of Th1 cytokines via JAK/STAT (Janus 
kinase/Signal Transducer and Activator of Transcription) signalling pathway and 
also induces expression of BAFF from airway epithelial cells [66] and salivary gland 
cells [75] through unknown mechanism. 
The Janus kinase/Signal Transducer and Activator of Transcription pathway 
transmits the extracellular chemical signals through the cell membrane and then to 
the nucleus and activates the targeted gene transcriptions. This signalling pathway 
induces cell proliferation, migration, differentiation and apoptosis. Activation occurs 
when ligand binds and induces multimerization of receptor subunits. Cytoplasmic 
domain subunits of induced receptors interact with the JAK tyrosine kinase 
[68,69,70].  JAK has a SH2 domain, which has tyrosine kinase activity and JAK can 
bind to cell surface receptors via this domain and autophosphorylates itself. JAK1, 
JAK2, JAK3 and Tyk2 are the members of JAK family in mammals. Activated JAKs 
phosphorylates receptors from their tyrosine residues. STATs are the transcription 
factors and are found in the cytoplasm until getting activated. They have an 
important role in signal transduction [70]. STATs can bind to induced receptors and 
that are phosphorylated by JAKs. Phosphorylated STATs form dimer with another 
phosphorylated STAT via SH2 domain and activated STAT dimer translocates to the 
nucleus and binds to the specific regions on DNA to activate or repress the target 
genes [71,72,73,74] (Figure 1.10).  
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1.7.3 Interferon Regulatory Factor 7 (IRF7) 
IRF7 is a member of the interferon regulatory transcription factor (IRF) family. It has 
been shown that NOD1 is induced by PAMPs or DAMPs from its LRR domain and 
gets self- oligomerized. NOD1 interacts with its downstream molecule RICK/RIP2 
and activates TAK1, which is an activator of the NFκB and MAPK pathways. It has 
been reported that Helicobacter pylori - infected gastric epithelial cells induce type I 
IFN signalling via NOD1 [62,63,65]. NOD1 becomes activated by H.pylori derived 
PGN and results in interaction between RICK and TRAF3. Following this 
interaction, TBK1, which is known as T2K and NAK, becomes activated. TBK1 is 
an essential serine-threonine kinase for IRF7 phosphorylation. Activated IRF7 
translocates to nucleus and initiates transcription of type I cytokines such as IFN-  
(interferon-alpha) and IFN-  (interferon-beta). This interferon regulatory 
transcription factor family member IRF7 is a critical transcription factor for IFN-  
expression. 
1.7.4 Interferon-beta (IFN-β) 
Interferons (IFNs) are divided into three subgroups: type I, type II and type III. Type 
I family members are IFN-α, IFN-β, IFN-ε, IFN-κ and IFN-ω. All type I IFNs binds 
to cell surface receptor called IFNAR (Interferon alpha / beta receptor alpha chain). 
This receptor consists of two subunits; IFAR1 and IFAR2. Type II IFN cytokine 
family member is IFN-  and it binds to IFNGR on the cell surface. IFNGR have 
IFNGR1 and IFNGR2 chains. The type III IFN group members are IFN-λ molecules 
called IFN-λ1, IFN-λ2 and IFN-λ3. Their receptors are IL10R2 and IFNLR1. 
 IFN-β is one of the member of type I cytokine family. These family members of 
cytokines are present in mammals, birds, amphibians and fish species. IFN-β 
cytokine is expressed by immune cells such as B cells, T cells, natural killer cells 
(NK), macrophages and some epithelial cells. IFN-β induction plays a role in innate 
immunity against bacterial infections and some viruses (e.g., influenza virus H5N1). 
PAMPs and DAMPs can be recognized by TLRs and NLRs and induce IFN-β 
secretion. Several studies showed that IRF7 is transcription factor for IFN-β 
[62,63,65]. Secreted IFN- β binds and activates its receptor IFNAR, which is 
localized on the cell. A member of the JAK family, JAK1 interacts with the activated 
IFNAR receptor, and then STATs can bind to receptor and induce JAK/STAT (Janus 
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kinase/Signal Transducer and Activator of Transcription) signalling pathway. 
Published studies showed that IFN-β gene expression is accomplished via 
JAK/STAT signalling pathway. IFN-β induces secretion of its own along with Th1 
cytokines in an autocrine manner. It was reported that activation of STAT1 by JAK1 
induces IFN-β expression in airway epithelial cells [66]. IFN-β also leads to complex 
formation of ISGF3 (interferon-stimulated gene factor 3), which is composed of 
STAT1, STAT2 and IRF9. This transcription factor is also important for Th1 
cytokine and IFN-β secretion against H.pylori and some other pathogens [67] (Figure 
1.9). 
1.8 The role of JAK/STAT signalling pathway on BAFF expression 
It has been reported that JAK/STAT signalling pathway is important for BAFF 
expression in airway epithelial cells. dsRNA – stimulation induces IFN-β secretion 
from airway epithelial cells [74]. Secreted IFN-  binds to its receptor on the cell 
surface and JAK1 interacts with IFNAR. STAT1 becomes activated and forms a 
dimer with other STAT molecules. Activated STAT dimers (either homo or 
heterodimers) can translocate to nucleus in order to induce IFN-stimulated response 
elements and initiate gene transcriptions of type I IFN cytokines (IFN-  and IFN- ). 
It was shown that IFN-  expression induces BAFF production in an autocrine 
manner. It has been also demonstrated that inhibition of IFN pathway reduces 
partially BAFF production in epithelial cells [75]. Intracellular signalling pathway 
that is responsible from induction of BAFF production and secretion from 
Helicobacter pylori- induced gastric epithelial cells still remains unclear. 
              
Figure 1.10 : JAK/STAT signalling pathway (adapted from ref. 74) 
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1.9 Aim of the Study 
BAFF is expressed by dendritic cells, macrophages, monocytes, neutrophils, cancer 
cells and epithelial cells and is known to be a vital cytokine for B cell maturation and 
survival. It was recently reported that H.pylori induces BAFF expression from 
gastric epithelial cell lines. However, BAFF production from H.pylori- stimulated 
gastric epithelial cell line has not been investigated yet. Also, the role of 
Helicobacter pylori Cag A virulence factor on BAFF expression, production, and 
BAFF signalling pathway in gastric epithelial cells still remain unclear. 
It was shown that JAK/STAT pathway plays a crucial role in BAFF expression from 
dsRNA- treated airway epithelial cells. The aim of this study is to determine the 
BAFF/APRIL expression and production level of H.pylori G27 WT- treated KATO-
III cells (gastric adenocarcinoma cell line). Then it is aimed to investigate the role of 
H.pylori virulence factor Cag A on BAFF/ APRIL expression and production. The 
aim also includes the investigation of BAFF signalling pathway in H.pylori - treated 
KATO-III cells. Based on previous studies on signalling pathways responsible for 
BAFF production from epithelial cells, JAK/STAT signalling pathway was selected 
for investigation. For this purpose, KATO-III cells were treated with Helicobacter 
pylori G27 WT in a time-dependent manner to investigate the exact time for 
noticeable BAFF expression. Then KATO-III cells were stimulated with H.pylori 
G27 WT and its mutant Cag A sonicate and the role of this H.pylori virulence 
factor on BAFF expression and secretion were investigated. In order to determine the 
role of JAK/STAT signalling pathway in our model, specific (JAK inhibitor) against 
JAK1 was used in a dose-dependent manner and its effect on STAT1 
phosphorylation was examined in H.pylori G27 WT- treated cells. Since BAFF 
expression was shown to be induced by various cytokines such as IFN- , 
involvement of IFN-  in BAFF expression from H.pylori sonicate- stimulated gastric 
epithelial cells was also investigated in this study. 
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2. MATERIAL AND METHODS 
2.1 Materials 
2.1.1 Helicobacter strains 
Helicobacter pylori strains: G27 (wild- type) and its CagA mutant were kindly 
provided by Prof. Anne Mü rich, Switzerland. 
Components of Helicobacter growth agar were given in Table 2.1. Antibiotics and 
components of antibiotic cocktails were shown in Table 2.2, 2.3. and 2.4 
respectively. For liquid culture of H.pylori, solutions are given in Table2.5. and the 
freezing solution ingredients are shown in 2.6. 
Table 2.1 : Components of Helicobacter growth agar. 
Component Amount 
Colombia agar 42,5 g 
Horse blood 50 ml 
β-cyclodexin 10 ml 
1000 X antibiotic cocktail 
200 X antibiotic cocktail 
1 ml 
5 ml 
Table 2.2 : Antibiotics used in Helicobacter agar. 
Antibiotic Supplier Company 
Trimethoprim HiMedia 
Amphotericin B HiMedia 
Vancomysin HiMedia 
Cefsulodin HiMedia 
Polymixin B HiMedia 
β-cyclodextrin HiMedia 
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    Table 2.3 : 1000X Antibiotic Cocktail. 
Content Amount 
Trimethoprim 100 mg 
Amphotericin B 160 mg 
DMSO 20 ml 
 
            Table 2.4 : 200X Antibiotic Cocktail. 
Content Amount 
Vancomysin 100 mg 
Cefsulodin 50 mg 
Polymixin B 3.3. mg 
ddH2O 50 ml 
  Table 2.5 : Solutions used for Helicobacter growth. 
Brucella Broth 50 ml 
FBS (10% (v/v)) 5 ul 
Vancomycin 5 ul 
   Table 2.6 : Freezing medium of Helicobacter pylori. 
Brucella Broth 25 ml 
Glyserol 25 ml 
 
2.1.2 KATO-III Cell Line 
The KATO-III human gastric adenocarcinoma cell line was kindly provided by 
Doç.Dr. Rengül Çetin Atalay at Bilkent University, Ankara, Turkey.  
2.1.3 Buffers and solutions 
2.1.3.1 Cell culture 
Table 2.7 : Solutions and media used in cell culture. 
0.5%Tyripsin-EDTA 10 X Lonza, Switzerland 
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DMSO Fisher Scientific 
Dulbecco s Modified Eagle Medium (DMEM) Lonza 
Fetal Bovine Serum (FBS) Lonza 
Penicilin / Streptomycin 100X GibcoBRL, USA 
 
Buffer and solutions used in cell culture experiments are given in table 2.8. 
Table 2.8 : Buffers and solutions used in cell culture. 
Freezing Medium % 50 FBS 
1X Pen/Strep 
DMEM 
%5 DMSO 
PBS 1X 9,55g in 1 L ddH2O 
 
2.1.4 Agarose Gel Electrophoresis 
Table 2.9 : Buffers and solutions used for agarose gel electrophoresis. 
50 X Tris Acetate acid EDTA(TAE) 242 g Tris base 
57.1 ml Glacial Acetic Acid 
100 ml 0.5 M EDTA 
up to 1L ddH2O 
DNA Ladder 100 bp DNA Ladder Mix 
GeneON, Germany 
Sybr Safe Invitrogen 
Loading Dye 6X Loading dye  
Fermantas, Canada 
 
2.1.5 Chemicals  
Chemicals used in this study are shown in Table 2.10. 
Table 2.10 : Chemical list in this study. 
Chemical Supplier Company 
Acetic Acid (glacial) Merck 
Agarose Lonza 
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dNTP GeneON 
EDTA Applichem 
Ethanol (absolute) Merck 
Sybr Safe DNA Gel Stain Invitrogen 
MgCl2 GeneON 
NaCl Merck 
Glycerol Merck 
Culture Media  
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Lonza 
Fetal Bovine Serum (FBS) Lonza 
Penicillin/Streptomycin 10X Gibco 
Trypan Blue Lonza 
Phosphate-Buffered Saline (PBS) Lonza 
Ammonium persulfate (APS) Fisher-Scientific 
Tween-20 Fisher-Scientific 
Bovine Serum Albumin (BSA) Santa Cruz 
DMSO Fisher Scientific 
Sodium Deodecyl Sulfate (SDS) Fisher Scientific 
TEMED Sigma-Aldrich 
Acrylamide- Bis-acrylamide (40%) Fisher Scientific 
Bromophenol Blue Fisher Scientific 
Nonfat dry milk powder Organic valley 
Protein Ladder New England Biolabs 
PMSF Applichem 
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                                 Table 2.10 (cont’d.) : Chemical list in this study. 
Nonidet P-40 (NP-40) Applichem  
HALT Protease Inhibitor (100X) Thermo Scientific 
PhosSTOP Phosphatase Inhibitor (10X)  Roche 
DTT Applichem 
β-Mercaptoethanol Sigma-Aldrich 
Ponceau S Fisher Scientific 
Methanol Sigma-Aldrich 
Isopropanol Sigma-Aldrich 
HCl Sigma-Aldrich 
NaOH Sigma-Aldrich 
Glycine Fisher Scientific 
Tris base (Trizma base) Sigma-Aldrich 
NaF Alfa Aesar 
Columbia Agar BD 
Brucella Broth BD 
CampyGen 2.5L Oxoid 
 
2.1.6 Protein isolation  
Whole Cell Extract (WCE) Buffer was used for protein isolations and the 
components & amounts used in this study are shown in Table 2.11. After protein 
isolation, protein concentrations were measured by BCA. Diluted scheme for BCA is 
given in Table 2.12. 
Table 2.11 : WCE components and amounts. 
Content Amount 
1 M HEPES 2 ml of 1M  
0.4 mM NaCl 8 ml of 5mM 
25% glycerol 25 ml of 50% glycerol 
1 mM EDTA 200 µl of 0.5 M 
15 mM NaF 100 µl of 0.5 M 
0.1 % NP-40 1 ml of 10% NP-40 
 
 24 
                            Table 2.11 (cont’d) : WCE components and amounts. 
ddH2O up to 100 ml 
10X Phosphatase Inhibitor Final concentration 1X 
100 X Protease inhibitor Cocktail Final concentration 1X 
 
                           Table 2.12 :  Dilution scheme for BCA Assay standards 
 
2.1.7 Western Blotting 
          Table 2.13 : Buffers, solutions and supplements used for Western Blotting 
Blocking Solution 1g non-fat dry milk powder 
in 20 ml 1X TBS-T 
Ponceau Staining Solution 0.1 g Ponceau S (0.1% (w/v)) 
5 ml Glacial Acetic Acid (5% (v/v)) 
up to 100 ml ddH2O 
Protein Ladder New England Biolabs 
10 X Running Buffer (pH 8.3) 
 
15 g Tris base (25 mM) 
71.2 g Glycine (192 mM) 
50 ml 10% SDS (0.1%) 
up to 1L ddH2O 
 
Vial Volume of diluents 
ddH2O (µl) 
Volume & source of BSA 
(µL) 
Final BSA 
Concentration 
(µg/ml) 
A 0 300 of stock 2,000 
B 125 375 of stock 1,500 
C 325 325 of stock 1,000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0 = Blank 
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 Table 2.13 (cont’d) : Buffers, solutions and supplements used for Western Blotting 
10X Transfer Buffer 58.2 g Tris Base 
29.3 g Glycine 
37.5 ml 10% SDS 
up to 1L ddH2O 
1X Transfer Buffer 100 ml 10 X Transfer Buffer 
200 ml Methanol 
700 ml ddH2O 
10 X TBS (Tris Buffered Saline) (pH:7.4) 24.23 g Tris Base 
80.06 g NaCl 
up to 1L ddH2O 
1X TBS/T 100 ml 10 X TBS 
900 ml ddH2O 
1ml Tween-20 
Laemmli Buffer 5X 1.5 g SDS 
3.75 ml 1 M Tris-HCl (pH 6.8) 
0.015 g   Bromophenol Blue 
1.16 g DTT 
7.5 ml Glycerol 
up to 15 ml total volume ddH2O 
%10 SDS-polyacrylamide Separation Gel 4 ml ddH2O 
3.3 ml 30% Acrylamide mix 
2.5 ml 1.5 M Tris (pH 8.8) 
0.1 ml 10% SDS 
0.1 ml 10% APS 
0.005 ml TEMED 
10% SDS-polyacrylamide Stacking Gel 3.4 ml ddH2O 
0.83 ml 30% Acrylamide mix 
0.63 ml 1 M Tris (pH 8.8) 
0.05 ml 10% SDS 
0.05 ml 10% APS 
0.006 ml TEMED 
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2.1.8 Primers 
Primers and sequences used in this study are given in below Table 2.14. 
   Table 2.14 : Primers and sequences used for qRT-PCR. 
Primer name Sequence (5’-3’) Species GC 
content 
Tm Product 
size 
BAFF fw ACCGCGGGACTGAAAATCT h 52.63% 59°C 129 bp 
BAFF rv TGCAATCAGTTGCAAGCAGTC h 47.62% 
APRIL fw ATAGCGCAGGTGTCTTCCAT h 50% 59°C 117 bp 
APRIL rv ACAGTTTCACAAACCCCAGGA h 47.62% 
NOD1 fw GTGGACAACTTGCTGAAGAATGAC h 45.83% 60 
0
C 108 bp 
NOD1 rv CTGTACCAGGTCCAGAATTTTGC h 47.83% 
IFN-  fw AATTGCTCTCCTGTTGTGCTTC h 45.45% 60 
0
C 133 bp 
IFN-  rv GCAGTATTCAAGCCTCCCAT h 50% 
IRF7 fw CACCCCCATCTTCGACTTCA h 55% 65 
0
C 
 
101 bp 
IRF7 rv CGAAGCCCAGGTAGATGGTATAG h 52.17% 
18SrRNA fw GGCCCTGTAATTGGAATGAGTC m/h 50% 59 
0
C 146 bp 
18s rRNA rv CCAAGATCCAACTACGAGCTT m/h 47.62% 
 
2.1.9 Antibodies and inhibitor 
Table 2.15 : Antibodies and inhibitor used in this study. 
Antibody Catalog number Supplier Company 
Rat anti-BAFF mAb ab16082 Cell Signaling 
Goat anti-BAFF mAb af124 R&D Systems 
Rabbit anti- APRIL mAb ab64967 Abcam 
Rabbit anti-GAPDH  5174 Cell Signaling 
Mouse total anti-STAT1 9176 Cell Signaling 
Rabbit phospho anti- STAT1 9177 Cell Signaling 
Anti-rat IgG, HRP-linked  
Antibody 
7077 
 
Cell Signaling 
Anti-rabbit IgG, HRP-linked  7074 Cell Signaling 
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                     Table 2.15 (cont’d) : Antibodies and inhibitor used in this study 
Anti-goat IgG, HRP-linked 
Antibody 
sc-2020 
 
Santa Cruz 
JAK Inhibitor cas457081-03-7 Santa Cruz 
 
2.1.10 Equipment 
The equipment used in this study is listed in Table 2.16. 
                               Table 2.16 : The equipment used in this study. 
Equipment Supplier Company 
Laminar Air Flow Cabinets FASTER BH_EN 2003 
Pipettes 10 µl, 20 µl, 100 µl, 200 µl, 1000 µl 
Socorex and 10 µl, 100 µl, 1000 µl 
Biohit 
Electronic Pipette CappAid 
Centrifuges Beckman Coulter Allegra ™ 25 R 
Centrifuge 
Scanspeed 1730 R 
Labogene Scanspeed mini 
Microplate Spectrophotometer BIO-RAD Benchmark Plus 
Microwave White-Westinghouse 
Eppendorfs Interlab 
Nitrocellulose Transfer Packs BIO-RAD 
Scale Precisa 
pH Meter  Mettler Toledo MP220 
Examination Gloves Beybi 
Incubator with CO2 BINDER 
Nitrogen tank  Air liquide 
Tissue culture flasks (25 cm
2
, 75 cm
2
) Sarstedt 
Culture plate (6-well, 12-well, 96-well U 
bottom, 96-well F bottom) 
TPP 
Petri dishes Isolab 
Serological pipette (5 ml, 10 ml, 25 ml) Sarstedt 
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              Table 2.16 (cont’d) : The equipment used in this study 
Centrifuge tubes Sarstedt, Isolab 
Anaerobic Jar Anaerocult 
Nitrocellulose Paper (0.2 µm pore size) Santa Cruz 
Thermo Cycler Techne 512 
Vortex Mixer Uzusio VTX-3000L,LMS 
Quick spin LMS 
Incubator  BINDER 
Whatman Filter Paper (3 mm) Whatman 
Magnetic stirrer WiseStir MSH-20D, Wisd  
pH Meter InoLab 
Light Microscope Olympus CH30 
Hemacytometer Isolab 
Ice Machine Scotsman AF10 Siemens (-20 
0
C) 
Haier (- 80 
0
C) 
Electrophoresis Gel System BIO-RAD 
SDS-PAGE Gel Electrophoresis System BIO-RAD 
UVIPhoto MW Version 99.05 
for Windows 95&98 
Microsoft 
Shakers Heidolp Duomax 1030 
Lightcycler 480 Roche 
Lightcycler 480 Multiwell plate Roche 
Lightcycler 480 Sealing foil 50 foils Roche 
Applied Biosystems Multiwell plate Applied Biosystems 
Applied Biosystems Sealing foil Applied Biosystems 
Kodak Medical X-Ray Processors Kodak 
Densitometer G8 8000 
Thermo shaker Biometra TS1 ThermoShaker 
Spectrophotometers Thermo Scientific Nanodrop 
TM 
 2000 c, 
BIO-RAD Benchmark Plus 
Sonicator Bandelin Sonopuls 
Nitrogen Tank Air Liquid 
Tissue flask Sarstedt 
Power Supply BIO-RAD 
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2.1.11 Commercial kits  
Commercial kits are given in below Table 2.17. 
Table 2.17 : Commercial kits used in this study. 
Kit Supplier Company 
Innu-Prep RNA Mini isolation Kit Analytic jena, Biometra 
High capacity cDNA syntesis Kit, 200 rxns Applied Biosystems 
Human BAFF ELISA Abcam 
Lightcycler 480 Sybr-Green I Master Roche 
Power SYBR® Green PCR Master Mix Applied Biosystems 
Maximo Taq mSuperHot GeneON 
20 X LumiGlo Reagent and 20 X Cell Signaling 
Pierce  BCA 
TM 
Protein Assay Thermo Scientific 
2.2 METHODS 
2.2.1 Maintenance of Helicobacter species 
Helicobacter pylori Wild type (G27) and its CagA mutant were kindly provided by 
Prof. Anne Müller at University of Zurich, Zurich, Switzerland. Bacteria were 
seeded on Columbia Agar plates for 2 days at 37 
0
C in the presence of Oxoid 
Campygen sheet. After 2 days, bacteria viability was checked under microscope and 
transferred to liquid culture containing Brucella broth, 10%FBS and vancomycin. 
2.2.2 Growth of Helicobacter strains 
2.2.2.1 Colombia agar preparation  
In order to growth Helicobacter pylori strains, 42,5 g Colombia agar was dissolved 
in 1000 ml water and autoclaved. Then the bottle was put in 50
0
C water for 1 hour. 
50 ml horse blood was added to agar. 5 ml β-cyclodexin was added on them. 0,5 ml 
of 1000 X antibiotic cocktail containing 100mg Trimethoprim and 160mg 
Amphotericin B and dissolve in 20ml DMSO and 2,5 ml from 200 X antibiotic 
cocktail containing 100mg Vancomycin, 50mg Cefsulodin, 3.3mg Polymixin B and 
dissolve in 50ml H2O was additionally added to H.pylori plates. 
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2.2.2.2 Liquid culture 
 
Helicobacter pylori strains were cultured in Brucella broth containing 10%FBS and 
10.000X vancomycin. Oxoid Campygen sheet was added on the aerobic jar and 
bacteria were left growing at 37 
0 
C. 
2.2.3 Sonication of Helicobacter pylori Strains 
Helicobacter pylori’s mobility was checked under light microscope. 120- 200 ml 
liquid culture of Helicobacter pylori was aliqouted to 15 ml falcons. Falcons were 
centrifuged at 3000 rpm for 10 minutes. Supernatants were discarded. 10 ml PBS 
was used to washing step and was centrifuged at 3000 rpm for 7 minutes. 
Supernatants were discarded. 3.5 ml PBS was added on pellet and mixed. Tube was 
taken to sonication on ice. Sonication was performed as 30 sec pulse on, 50 sec pulse 
off for 6.30 minutes at 50 watt (MS 72 probe was used). They were aliquoted to 1.5 
ml eppendorfs at 500 µl for each and then were centrifuged at 15000rpm for 20 
minutes. Supernatant is taken to new eppendorf tubes and their concentrations were 
measured with BCA. 
2.2.4 Protein Bicinchoninic Acid (BCA) Assay 
The bicinchoninic acid assay (BCA) is similar to Bradford assay. This technic is used 
for the determining the total concentration of protein in a solution. After sonication 
of Helicobacter pylori strain, their concentrations were measured with Thermo 
Scientific’s Pierce Protein BCA Assay Kit. Bovine Serum Albumin (BSA) standards 
(prepared from 2000 µg/ml top standard solution were prepared as 0 g/ml, 25 g 
/ml, 125 g /ml, 250 g/ml, 500 g/ml, 750 g/ml, 1000 g/ml, 1500 g/ml, 2000 
g/ml with dilution instructions provided by the manufacturer, working reagent (200 
µl per sample) and samples were prepared. Working reagent was a mixture of 
Solution B and Solution A with a ratio of 1:50, respectively. Standards and samples 
were used as duplicates. Prepared working reagent was added to each 96-well F 
bottom plate as 200 µl. Then 10 µl of each standard and diluted samples were added 
into the corresponding wells. Plate was covered and incubated at 37°C for 30 
minutes. After 30 minutes incubation, absorbances of proteins were measured at 562 
nm at Microplate Reader.   
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2.2.5 Cell Culture 
2.2.5.1 Maintenance of KATO-III Cell Lines 
KATO-III cells were grown in complete DMEM (supplemented with %10 FBS, 
2mM L-Glutamine, 1 X Penicillin and Streptomycin). Cells were grown at 37 
O
C and 
5% CO2  incubator. Trypsin was used to subculture. KATO-III cells were frozen in 
freezing medium containing complete DMEM with %50 FBS and %10 DMSO. 
2.2.5.2 Cell thawing 
9 ml required DMEM medium was added to a 15 ml falcon tube. Frozen cells were 
thaw with the heat of your hand briefly. The cells were dissolved with complete 
DMEM medium. The falcon tube was centrifuged at 900 rpm for 5 min to remove 
DMSO (which is toxic for cells) from cells. The supernatant was discarded carefully 
following centrifugation. ~5 ml fresh DMEM medium for T25 flask or ~12 ml fresh 
DMEM medium for T75 flask was added to the pellet and the pellet was dissolved in 
the medium. The viability of cells was checked under the microscope before placing 
the flask to the incubator (37°C + 5% CO2). 
2.2.5.3 Cell passage 
Cell density was determined on light microscope. Suspension KATO-III cells were 
put on a 15 ml falcon tube and centrifuged at 900 rpm for 5 minutes. The supernatant 
was discarded and the pellet was dissolved in 1 ml culture medium. The flask was 
washed once with 12 ml 1X PBS and 1500 µl of trypsin 100X was added on flask. 
The flask was incubated at 37 
0
C for 4 minutes. Then the flask was taken and 
mechanic force was applied to flask. 2,5 ml of culture medium and 1 ml dissolved 
cells were added to inhibit the effect of trypsin. 1ml cells (2x10
6
 cells) were taken in 
a new flask with a fresh culture medium 
2.2.5.4 Cell freezing 
The medium was discarded from the flask. PBS was added flask to wash cells, then 
discard PBS. 1,5 ml trypsin was added to T75 flask and incubate the flask for 4 min. 
at 37°C. Attachment of cells were controlled under the microscope. 
Approximately 9 ml DMEM medium to T75 flask to inactivate trypsin and transfer 
the mix into a 15 ml falcon tube. Cells were centrifuged at 900 rpm for 5 min. 
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The supernatant was discarded and 500 µL-1000 µL freezing medium was added 
(supplemented with growth media and 10% DMSO) to the pellet and dissolve the 
pellet in the freezing medium. Frozen cells were stored at -80°C. 
2.2.5.5 Cell counting 
Growth medium was removed from the flask and washed once with 1X PBS. 1.5 ml 
of Trypsin treatment from 10X stock was added to flask to breaks down the 
disulphate bounds and waited 4 min. at 37
0
C incubator. Then 4 ml growth medium 
was added to the flask for inhibition of Trypsin solution.10 µl suspension was taken 
into 1.5 µl eppendorf tube and 1µl of trypan blue was added to check the viability of 
cells. Then 10 µl of cell suspension was put onto the hemacytometer and the cells 
were counted. 
2.2.5.6 Treatment of KATO-III cells with Helicobacter pylori Sonicates 
KATO-III cells were seeded on 6-well plates as 5x10
5
 cells/well one day before the 
treatment. The gastric adenocarcinoma cells were treated H.pylori G27 (wild- type) 
sonicate and its Cag A sonicate for 24 h. 
2.2.5.7 Cell Harvesting 
After 24 h waited treatment, 6-well plates were checked under microscope. 
Suspension cells were collected in a 1.5 ml eppendorf tubes and centrifuged at 3000 
rpm for 8 minutes. Supernatants were discarded and cell pellet was dissolved in 500 
µl of culture medium. 6-wells were washed with 1ml 1X PBS. 400 µl of trypsin was 
added to wells and incubated at 37 
0
C for 4 minutes. After the incubation, 1ml 
culture medium was added into wells. Cells from wells and also dissolved cells were 
transferred into 2 ml eppendorf tubes. They were centrifuged at 3000 rpm for 8 
minutes. The supernatants were discarded. Cell pellets were put on -80 
0
C for further 
experiments. 
2.2.6 RNA isolation from eukaryotic KATO-III cells 
RNA isolations were performed by using Innu-prep RNA Mini kit (Analyticjena, 
Biometra Germany). 400µl of Lysis RL Solution was added onto the cell pellet and 
incubated for 2 minutes at room temperature. Cell pellet was re-suspended 
completely up and down by pipetting. The sample was incubated 3minutes at room 
temperature. A Spin D Filter was placed into a 2 ml Receiver tube.  The lysed sample 
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was transferred onto the Spin Filter D and the tube was centrifuged at 10.000x g 
(12.000 rpm) for 2 minutes. Spin D Filter was discarded. The filtrate was not 
discarded because the filtrate contains the RNA. A Spin Filter R was placed in a new 
2 ml receiver tube. An equal volume (app.400 µl) of 70% ethanol was added to the 
filtrate. The sample was mixed by pipetting sometimes up and down. The sample 
was transferred onto the Spin Filter R and centrifuged at 10.000 x g for 2 minutes. 
2ml receiver tube was discarded and Spin Filter R was placed in new receiver tube. 
The Spin Filter R was opened and 500 µl Washing solution HS was added. The cap 
was closed and centrifuged at 10.000 x g for 1 minute. The receiver tube was 
discarded with filtrate and new one was placed. The Spin Filter R was opened and 
700 µl Washing solution LS was added. The cap was closed and centrifuged at 
10.000 x g for 1 minute. The receiver tube was discarded with filtrate and new one 
was placed. The tube was centrifuged at 10.000 x g for 3 minutes to remove all traces 
of ethanol. The receiver tube was discarded. The Spin Filter R was placed into a 1.5 
ml Elution tube. The cap of Spin Filter R was opened carefully and 30-80 µl of 
RNase- free water was added. The tube was incubated at room temperature for 1 
minute and centrifuged at 6.000 x g for 1 minute. 
2.2.7 cDNA Synthesis 
After RNA isolation and nanodrop measurements, samples were calculated as total 
RNA would be 1 µg and then ddH2O to obtain 10 µl final volume for each tube. 
Reagents for cDNA synthesis is given in Table 2.18 and cDNA PCR conditions are 
given Table 2.19. 
                                      Table 2.18 : Reagents for cDNA synthesis. 
Components Reaction Volume 
Buffer 2 µl 
dNTP 0,8 µl 
OligodT 1 µl 
Reverse Transcriptase 1 µl 
RNase Inhibitor 0,125 µl 
ddH2O 5,075 µl 
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             Table 2.19 : cDNA PCR conditions. 
25 
0
C 37 
0
C 80 
0
C 4 
0
C 
10 min 120 min 5 min ∞ 
 
2.2.8 Primer design 
Forward and reverse primers specific for expression of BAFF, APRIL, NOD1,     
IFN- , IRF7 and 18S rRNA were design by using Primer blast program. Melting 
temperatures and GC content of primers, self-dimer formation were checked. All 
primers are given in Table 2.14. 
2.2.9 18S rRNA PCR  
Polymerase Chain reaction (PCR) is developed in 1983 by Kary Mullis. Specific 
DNA regions can be amplified by the in vitro enzymatic replications. PCR is 
composed of three steps including denaturation, annealing and extension. In 
denaturation step, two DNA strands were separated at 94 
0
C. Specifically designed 
primers were bind to complementary region of the DNA in the annealing step.   
Annealing temperatures change according to primers melting temperature. Extension 
and final extension steps occur at 72
0
C.  
In order to check the cDNA, 18S rRNA primers were used for the conventional PCR. 
18S rRNA primers are given in Table 2.14. Required PCR reagents are shown in 
below Table 2.20. and Conventional PCR conditions  are indicated Table 2.21. 
                                           Table 2.20 : Reagents for PCR. 
Components Reaction Volume 
10 X Taq Buffer 2,5 µl 
MgCl2 (25 mM) 1,5 µl 
dNTP (10 mM) 0,5 µl 
Forward Primer (10 µM) 0,75 µl 
Reverse Primer (10 µM) 0,75 µl 
Maximo Taq 0,1 µl 
ddH2O 17,9  µl 
Template 1 µg 
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                                  Table 2.21 : Conventional PCR conditions. 
Initial Denaturation 95 
o
C 5 min. 1 cycle 
Denaturation 95 
o
C 30 sec.  
35 cycle Annealing 59 
o
C 30 sec. 
Extension 72 
o
C 45 sec. 
Final extension 72 
o
C 7 min 1 cycle 
Hold 4 
o
C ∞ - 
 
2.2.10 Agarose Gel Electrophoresis 
2% agarose gel is sufficient for the observation of our expected PCR products. The 
agarose gel contains 2 g agarose in 100 ml 1X TAE. The gel solution was boiled in 
the microwave until the agarose was dissolved. After the cooling, 10 µl sybr safe 
solution was added in to the gel and poured in to the gel cassette. Marker was loaded 
as 2.5 µl always in the first well of the gel to evaluate the length of the PCR 
products. 7.5 µl PCR products were mixed with 1.5 µl 6X loading dye. Loading dye 
was used to facilitate the observation. Gel was run at 110 V for 17 minutes. The 
bands, which are Sybr- safe stained was observed with UVtrans- illuminator by the 
help of UV PhotoMW software. 
                                      Table 2.22 :  Agarose gel preparation. 
Components Amounts 
1X TAE 100 ml 
Agarose 2 g 
Sybr safe  10 µl 
6X loading dye (Fermantas) 1.5 ul 
Template 7.5 ul 
 
2.2.11 Real-time PCR 
qRT-PCR which is a short name of  quantitative Real-time PCR, a technique that 
based on the PCR. qRT-PCR is used to amplify and simultaneously quantify the 
DNA target molecule. In this study, expression levels of target genes were 
normalized to their house- keeping gene.  Sybr Green I is used as a nucleic acid stain 
in these RT-PCR experiments. Sybr Green I is a dye which binds to DNA and gives 
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the emission that can be detected. 18S rRNA was used as a reference gene for qRT-
PCR. qRT-PCR’s were performed in Roche Light Cycler 480-II. qRT-PCR reagents 
are indicated in Table 2.23. The Light Cycler program is given in the Table 2.24.  
    Table 2.23 : qRT-PCR reagents. 
Components Amounts 
cDNA 2.5 µl 
Forward Primer (10 µM) 
Reverse Primer (10 µM) 
0.5 µl 
0.5 µl 
Sybr Green I Master Mix 5 µl 
ddH2O 1.5 µl 
Total mix 10 µl 
 
Reaction mix was added to each well as 7.5 µl and then 2.5 µl of cDNAs were 
started to put as duplicates. Plate was covered with the seal and centrifuged at 1000 
rpm for 1 min. 
Table 2.24 : Real-time PCR conditions. 
Step Temperature Time Cycle 
Initial denaturation 95 
0
C 1 min 1 
Denaturation 95 
0
C 15 sec. 45 
Amplification 59 
0
C 1 min 
Extension 72  
0
C 1 min 
 
For analysing the results, concentration of target genes normalized to reference gene. 
Efficiency values and the error rates were in expected ranges. 
 
 37 
2.2.12 Protein isolation 
For protein isolation, pellets were resuspended in Whole Cell Extract Buffer (WCE) 
containing freshly added 0.1 M PMSF (final conc.: 0.5 mM), 100X HALT Protease 
Inhibitor Cocktail (final conc.: 1X) and 10X Roche Phosphatase Inhibitor Cocktail 
(final conc.: 1X). Samples were incubated on ice for 30 min. Then they were 
centrifuged at 14000 rpm for 10 min. Supernatants were aliquoted as total protein 
samples and stored at -80°C. Protein concentrations were determined by Protein 
BCA Assay. 
2.2.13 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western       
           Blotting 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis is a technique 
widely used to separate proteins according to electrophoretic mobility. The proteins 
are separated in gel according to their size. In this study, 5% stacking gel and 10 % 
separating gel were used. Prepared gels were poured between SDS-glasses and left 
for polymerization. After the polymerization, samples were mixed 5X Laemmli 
Buffer and boiled at 100°C for 5 minutes. The gels were placed into the tank and 
were run in running buffer at 90V-150V for approximately 2 h.  
In order to detect the specific proteins Western Blot technique is used in this study. 
After SDS-PAGE, proteins were transferred from gel to the nitrocellulose membrane 
using Wet Transfer blotting (at 160V for 1h at 4°C). Transferred proteins were 
stained with Ponceau S. After visualizing the proteins, membrane was blocked at 
4°C overnight in blocking solution (TBS/T containing 5% non-fat dry milk) to 
prevent non-specific binding. Then its incubated with 1:1000-1:2000 diluted primary 
antibodies (in TBS/T containing 5% BSA) at 4°C overnight with gentle shaking. The 
day after, membrane was washed with TBS-T buffer 3 times for 10 minutes in the 
shaker. 1:3000 diluted secondary antibody which was conjugated with HRP enzyme 
prepared again in blocking solution and then membrane was incubated with 
secondary antibody solution for 1-2 hour at 4°C in the shaker. After washing steps of 
membrane 3 times with TBS/T, the HRP substrate 20X LumiGLO ® Reagent (Cell 
Signaling) was diluted in to 1X with distilled sterile water (ddH2O). This substrate is 
required for the visualization of the proteins. The membrane was exposed to X-ray 
film and then developed in Kodak Medical X-ray Processor according to 
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manufacturer’s instruction. For the detection of other proteins in the same 
membrane, membrane can wash with TBS/T and can be incubated in other primary 
antibody. 
2.2.14 BAFF ELISA 
In order to determine the amount of secreted BAFF levels from gastric epithelial cell 
line, KATO-III, supernatants of treated and untreated cells were used in Human 
BAFF ELISA. ELISA (Enzyme-Linked Immunosorbent Assay) is a quantitative 
method that can be detect secreted proteins. 
All reagents, working standards and samples were prepared to room temperature. 
Standards were serially diluted before use. 10 ng/ml Stock standard was prepared by 
reconstituting one vial of the BAFF standard with the addition of 1 mL Sample 
Diluent Buffer and hold at room temperature for 10 min. Standard tubes were 
labelled with 1 to 8. 400 μL of the 10 ng/mL Stock Standard was put into standard 
tube #1 and mixed with 600 μL Sample Diluent Buffer. 300 μL of sample diluent 
buffer was added into #2 to #8 standard tubes. Standard #2 was prepared by 
transferring 300 μL from standard #1 to standard #2. Standard #3 was prepared by 
transferring 300 μL from standard #2 to standard #3. Serial dilutions were repeated 
for tubes #4 to #7. Standard #8 is the blank control. 
                      Table 2.25 : Standard preparation of Human BAFF ELISA. 
Standard# Sample to 
Dilute 
Volume to 
Dilute (μL) 
Volume of 
Diluent (μL) 
Starting 
Conc.(pg/ml) 
Final 
Conc.(pg/ml) 
1 Stock 400 600 10,000 4,000 
2 Standard #1 300 300 4,000 2,000 
3 Standard #2 300 300 2,000 1,000 
4 Standard #3 300 300 1,000 500 
5 Standard #4 300 300 500 250 
6 Standard #5 300 300 250 125 
7 Standard #6 300 300 125 62,5 
8 None - 300 - - 
 
After standard preparation, 100 μL of standard and undiluted samples were added to 
wells, which were pre-coated with specific mouse monoclonal anti BAFF antibody. 
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Plate was covered and incubated at 37 
0
C for 90 min. Cover was removed and 
contents were discarded from each well, plate was blotted onto paper towels. Wells 
do not let completely dry. 100 μL of 1X Biotinylated anti-Human BAFF antibody 
was added into each well and the plate was incubated at 37°C for 60 minutes. Plate 
was washed 3X with 1X PBS. Washing buffer was stayed in wells for one minute. 
Washing buffer was discarded and the plate was blotted onto paper towels. 100 μL of 
1X Avidin-Biotin-Peroxidase Complex working solution was added into each well 
and incubated at 37°C for 30 minutes. Plate was washed 5X with 1X PBS and 
washing buffer was discarded as previously described. 90 μL of prepared TMB 
colour developing agent was added into each well and the plate was incubated at 
37°C in dark for 20 - 25 minutes. 100 μL of prepared TMB Stop Solution was added 
into each well and the colour changes into yellow were seen immediately. The 
absorbance at 450 nm was read in a microplate reader within 30 min. after adding 
stop solution. 
2.2.15 Densitometric analyses 
Densitometric analyses were performed to detect the densities of protein bands of the 
target proteins and normalize their density to that of housekeeping protein (GAPDH). 
X-ray films were scanned in Bio-Rad GS-800 densitometer and densitometric 
analyses were performed using Adobe PhotoShop CS5 Software. Densitometric 
values of protein bands were determined by multiplying index and mean levels of 
each protein band and these values were normalized to their corresponding 
housekeeping controls (GAPDH levels). Phosphorylation percentages of target 
proteins were determined by the ratio of densitometric values of phospho-proteins 
over total-proteins normalized to their internal control. Phosphorylation percentages 
were graphed using GraphPad Prism 5.0 software. Standard deviations of the mean 
are indicated by vertical bars in column bar graphs. 
2.2.16 Statistical analyses     
All p values were calculated using GraphPad Prism 5.0 software. Significancies were 
determined by Student t test. In all analyses, a two-tailed p-value of less than 0.05 
was considered statistically significant. In column bar graphs, vertical bars indicate 
standard deviations of the mean, n.s. denotes not significant. 
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3. RESULTS 
3.1 Effect of H.pylori on BAFF expression in KATO-III cells  
3.1.1 Investigation of BAFF expression from H.pylori G27 WT sonicate- treated     
          KATO-III gastric epithelial cells in a time-dependent manner 
It was reported that H.pylori induces the BAFF expression from other gastric 
epithelial cell lines [76].  In order to assess BAFF expression from H.pylori G27 WT 
sonicate- treated gastric epithelial cells, human KATO-III cells were investigated for 
BAFF expression on RNA level in a time-dependent manner upon Helicobacter 
pylori- infection (Figure 3.1). 
  
Figure 3.1 : Treatment with H.pylori G27 WT sonicate leads to BAFF expression in 
                   in KATO-III cells. KATO-III cells were seeded on 6 - well plates as 
                   5x10
5 
cells and they were treated with H.pylori G27 WT sonicate (10 
                   g/ml) or left unstimulated (medium) in a time- dependent manner.  
                   Then, cells were harvested at indicated time-points (6 h, 24 h, 48 h and       
                   72 h) and RNA isolations were performed. Following RNA isolations,  
                   they were converted to cDNA and analysed for BAFF and 18S rRNA     
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    expressions using realtime - PCR. 18S rRNA was used as a reference gene for     
    qRT-PCR. For every each sample BAFF concentrations were normalised to 18S    
    rRNA concentrations. Results are graphed using Graphpad Prism 5.0. Statistical    
    analysis was conducted using Student’s t-test. Figure represents three independent  
    experiments (n=3), n.s.: not significant. 
BAFF mRNA expression level was significantly 2- fold increased in H.pylori G27 
WT sonicate- treated cells compared to untreated control at 24 h in KATO-III cells. 
It was observed that BAFF mRNA expression levels were not significantly induced 
in other indicated time points. This result suggests that Helicobacter pylori G27 WT 
sonicate can induce BAFF expression from KATO-III cells. Further experiments 
were performed at 24 hours. 
3.1.2 Effect of H.pylori virulence factor Cag A on BAFF expression in KATO-III     
         cells 
Cag A is a well – known virulence factor of H.pylori. The effect of Cag A on BAFF 
expression is not- defined in gastric epithelial cells. In order to assess the effect of 
H.pylori virulence factor Cag A on BAFF expression, KATO-III cells were 
investigated for expression of BAFF upon stimulation with Helicobacter pylori G27 
WT or its Cag A mutant strains sonicates at 24 h time point. Figure 3.2 indicates the 
BAFF expression levels of H.pylori G27 WT sonicate, H.pylori G27 ΔCag A 
sonicate- treated or untreated KATO-III cells. 
 
  Figure 3.2 : BAFF expression level is significantly decreased in H.pylori G27 Cag  
                     A sonicate treated KATO-III cells at 24h. KATO-III cells were seeded  
                    on 6 - well plates as 5x10
5 
cells and were treated with H.pylori G27 WT        
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      sonicate and H.pylori G27 isogenic mutant Cag A (lacks of cagA gene- ΔCag A)    
      at 10 g/ml final concentration or left untreated (medium) for 24 h. Cells were  
      harvested at 24 h and RNA isolations were performed. Isolated RNAs were  
      converted to cDNA and BAFF, 18S rRNA expression levels were determined by  
      qRT -PCR. 18S rRNA was used as an endogenous control. BAFF mRNA  
      expression levels were normalized to endogenous control. Results are graphed  
      using Graphpad Prism 5.0. Statistical analysis was conducted using Student’s t- 
      test. Data are representative of three independent experiments (n=3), n.s.: not   
      significant. 
BAFF expression level was significantly 1.7- fold increased in H.pylori G27 
sonicate- treated cells compared to untreated cells at 24 h time-point. There was no 
significant induction of BAFF expression in H.pylori G27 ΔCag A sonicate- treated 
cells compared to untreated cells. This study represents the importance of H.pylori 
virulence factor Cag A on BAFF expression in KATO-III cells.  
3.2 Effect of H.pylori sonicate- treated KATO-III cells on BAFF production 
3.2.1 H.pylori sonicate induced membrane-bound and soluble BAFF production 
H.pylori induction causes BAFF expression in RNA level from gastric epithelial cell 
line (MKN28) [76]. However, production of BAFF in protein level has not been 
reported. In order to assess effect of H.pylori sonicates on BAFF production, KATO-
III cells were treated with H.pylori G27 WT sonicate and H.pylori G27 ΔCag A 
sonicate at 24h. Then BAFF protein levels were detected upon stimulation with 
H.pylori G27 WT sonicate and H.pylori G27 ΔCag A sonicate by Western Blotting 
(Figure 3.3). To determine different forms of BAFF protein, different BAFF 
antibodies targeted against membrane-bound BAFF and soluble BAFF proteins were 
used. 
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Figure 3.3 : BAFF protein level is significantly decreased in H.pylori G27 Cag A  
                    sonicate treated KATO-III cells at 24h. Cells were stimulated with     
                    H.pylori G27 WT sonicate and H.pylori G27 ΔCag A at 10 g/ml final  
                    concentration or left untreated (medium) for 24 h. KATO-III cells were  
                    harvested for protein isolations and culture supernatants were aliquoted  
                    for detection of sBAFF on SDS-PAGE. Cells were lysed and  
                    immunoblotted for membrane-bound BAFF (32 kDa). Supernatants  
                    were immunoblotted for soluble BAFF (17 kDa). GAPDH (37 kDa) and  
                    Ponceau S were used as loading controls respectively. Results are  
                    graphed using Graphpad Prism 5.0. Statistical analysis was conducted  
                    using Student’s t-test. Data are representative of two independent  
                    experiments (n=2), n.s.: not significant. 
According to our results membrane- bound BAFF was 1.2- fold increased in H.pylori 
G27 WT sonicate- treated KATO-III cells compared to untreated cells. sBAFF 
Western Blotting results shows 1.7-fold significant increase of BAFF protein from  
H.pylori G27 WT sonicate- treated cells compared to untreated controls. It was 
observed that mBAFF production was not increased in H.pylori G27 ΔCagA 
sonicate- treated cells compared to untreated cells. Soluble BAFF was not detected in 
untreated control. Both H.pylori G27 WT and H.pylori G27 ΔCagA sonicate induce 
soluble BAFF production. However, secreted sBAFF was 2.4-fold increased in 
H.pylori G27 WT sonicate- treated KATO-III cells when compared to H.pylori G27 
ΔCagA sonicate- treated cells. Overall, our data indicate the role of Cag A on BAFF 
production and secretion from H.pylori sonicates- treated KATO-III cells. 
 
 
 
n.s 
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3.2.2 Effect of H.pylori sonicate on BAFF secretion in KATO-III cells 
In order to confirm the BAFF secretion from H.pylori G27 WT sonicate- treatment in 
KATO-III cells and effect of H.pylori virulence factor CagA on BAFF secretion, 
BAFF ELISA (Abcam) was performed from culture supernatants of H.pylori 
sonicates- treated or untreated cells (Figure 3.4). 
 
Figure 3.4 : BAFF secretion is significantly induced in H.pylori G27 WT sonicate-   
                   treated KATO-III cells. KATO-III cells (5x10
5 
cells/well) were incubated   
                   for 24 h with H.pylori G27 WT sonicate (10 g/ml), and H.pylori G27  
                   ΔCagA sonicate 10 μg/ml) or left untreated (medium). Secreted BAFF  
                   levels were detected by ELISA in culture supernatants of KATO-III cells  
                   treated with H.pylori sonicates. Results are graphed using Graphpad  
                   Prism 5.0. p values were determined by Student’s t-test. 
As expected, BAFF secretion level was significantly 4-fold increased in H.pylori 
G27 WT sonicate- treated cells compared to untreated cells. BAFF secretion level 
was not induced in H.pylori G27 ΔCag A sonicate- treated cells as much as H.pylori 
G27 WT sonicate treatment. This result indicates that stimulation of gastric epithelial 
cells with H.pylori G27 WT sonicate induces BAFF secretion at 24 h. 
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3.3 Effect of H.pylori on APRIL expression in KATO-III cells 
 
3.3.1 Investigation of APRIL expression from H.pylori G27 (WT) sonicate     
         treated KATO-III gastric epithelial cells in a time-dependent manner 
  
It was shown in this study that H.pylori- stimulated gastric epithelial cells 
significantly express BAFF at 24 h (Figure 3.1). APRIL is a homologue cytokine of 
BAFF and also expressed by epithelial cells [36]. For that reason, APRIL expression 
levels were investigated in KATO-III cells, which were treated with H.pylori G27 
WT sonicate. In order to determine APRIL expression levels from KATO-III cells 
stimulated by H.pylori G27 sonicate in time-dependent manner via qRT-PCR (Figure 
3.5). 
 
 
Figure 3.5 : Treatment with H.pylori G27 WT sonicate leads to APRIL expression in  
                     KATO-III cells. KATO-III cells (5x10
5
 cells/well) were stimulated with  
                     H.pylori G27 sonicate (10 g/ml ) final concentration or left  
                     unstimulated (medium). Then, cells were harvested at indicated time- 
                     points (6 h, 24 h, 48 h and 72 h) and RNA isolations were performed.  
                     Following RNA isolations, they were converted to cDNA and analysed  
                     for BAFF and 18S rRNA expressions using qRT-PCR. 18S rRNA was  
                     used as endogenous control. Results are graphed using Graphpad Prism  
                     5.0. p values were determined by Student’s t-test. Figure 3.5 represents  
                     three independent experiments (n=3), n.s: not significant. 
It was observed that APRIL mRNA expression levels were lower than BAFF 
expression levels (Figure 3.1). APRIL mRNA expression level was significantly 1.2 
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fold increased in H.pylori G27 WT sonicate- treated cells only at 24 h time-point. At 
other time points APRIL expression levels were not induced in H.pylori G27 WT 
sonicate- treated samples compared to untreated controls. These results indicate that 
APRIL is induced by H.pylori G27 WT sonicate treatment in KATO-III cells at 24 
hours. Therefore, we treated KATO-III cells with H.pylori sonicates at 24 hour time-
point in our further experiments. 
3.3.2 Effect of H.pylori virulence factor Cag A on APRIL expression in 
         KATO-III cells 
H.pylori virulence factor Cag A plays a role in development of gastric malignancies 
such as gastric cancer [6]. Figure 3.2 shows the importance of Cag A on BAFF 
expression. Also, the presence of Cag A has an effect on BAFF production and 
secretion in KATO-III cells at 24 h (Figure 3.2).  In order to assess the effect of Cag 
A on APRIL expression, KATO-III cells were stimulated with H.pylori G27 WT 
sonicate and H.pylori G27 ΔCag A sonicate at 24 hours. APRIL expression levels 
were detected by qRT-PCR (Figure 3.6). 
 
 
Figure 3.6 : APRIL expression level is decreased in H.pylori G27 Cag A sonicate    
                    treated KATO-III cells at 24h. KATO-III cells (5x10
5 
cells/ml) were  
                    stimulated for 24 h H.pylori G27 WT sonicate (10 μg/ml), and H.pylori   
                    G27 ΔCag A sonicate(10 μg/ml) or left untreated (medium). Cells were   
                    harvested at 24h and RNA isolations were performed. Isolated RNAs  
                    were converted to cDNA and APRIL, 18S rRNA expression levels were  
                    determined by qRT-PCR. 18S rRNA was used as endogenous control.     
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     APRIL mRNA levels were normalised to 18S rRNA concentrations. Results     
    are graphed using Graphpad Prism 5.0. Statistical analysis was conducted using    
    Student’s t-test. Data are representative of three independent experiments (n=3),     
    n.s: not significant. 
Expression levels of APRIL were found to be less than BAFF expression levels. 
APRIL expression level was significantly 1.2-fold increased in H.pylori G27 WT 
sonicate- treated KATO-III cells compared to untreated cells. There was no 
significant induction of APRIL expression level in H.pylori G27 ΔCag A sonicate- 
treated cells compared to untreated cells. Our results show the effect of H.pylori 
virulence factor Cag A on APRIL expression in KATO-III cells.   
3.4 Effect of H.pylori sonicate- treated KATO-III cells on APRIL production 
3.4.1 Effect of H.pylori virulence factor CagA on APRIL production  
Our previous results showed that H.pylori G27 WT sonicate- treated KATO-III cells 
express APRIL cytokine and H.pylori virulence factor Cag A has an effect on APRIL 
expression (Figure 3.5 and Figure 3.6). In order to confirm the Cag A effect on 
APRIL production, KATO-III cells were treated with H.pylori G27 WT sonicate and 
H.pylori G27 ΔCag A sonicate for 24 hours. APRIL production levels were 
investigated by Western Blotting (Figure 3.7). 
 
Figure 3.7 : APRIL protein level doesn’t change in H.pylori G27 ΔCag A sonicate    
                    treated KATO-III cells at 24h. Cells (5x10
5
 cells/well) were seeded on 6-   
                    well plates and stimulated for 24 h with H.pylori G27 WT sonicate (10   
                    μg/ml), H.pylori G27 ΔCagA sonicate (10 μg/ml) or left untreated     
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    (medium).KATO-III cells were harvested for protein isolations and  
    culture supernatants were aliquoted for detection of sBAFF on SDS-PAGE. Cells   
    were lysed and immunoblotted for APRIL (22 kDa). GAPDH (37 kDa) was used  
    as loading control. Samples were loaded as 20 μg. Densitometric analysis was   
    performed by using GAPDH as endogenous controls for APRIL. Results are  
    graphed using Graphpad Prism 5.0. Statistical analysis was conducted using  
    Student’s t-test. Data are representative of two independent experiments (n=2),  
    n.s: not significant.  
According to our results, APRIL production was significantly 2-fold increased in 
H.pylori G27 WT sonicate- treated KATO-III cells compared to untreated cells 
whereas H.pylori G27 ΔCag A sonicate- treated cells had no effect on APRIL 
production in KATO-III cells compared to untreated control. It was observed that 
H.pylori G27 WT sonicate- treated KATO-III cells produce APRIL protein at 24 h 
time-point. Overall, our results indicate the role of Cag A on APRIL production in 
H.pylori sonicate- treated KATO-III cells. 
3.5 H.pylori G27 WT sonicate induces NOD1 expression in KATO-III cells 
3.5.1 Effect of H.pylori G27 WT sonicate on NOD1 expression in a time-   
         dependent manner  
Up to this point, BAFF and APRIL expression were shown to be Cag A dependent 
both in RNA and protein level. It has been reported that H.pylori has a role in 
induction of NOD1 expression from gastric epithelial cells [62]. NOD1 signalling 
can both activate the production of pro-inflammatory cytokines via canonical NF- b 
pathway or type I cytokines such as IFN-  via IRF signalling. In order to determine 
the role of H.pylori G27 WT sonicate on NOD1 expression and NOD1 signalling 
pathway, KATO-III cells were treated with H.pylori G27 WT sonicate in a time- 
dependent manner. NOD1 mRNA expression levels were detected by qRT-PCR. 
(Figure 3.8) 
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Figure 3.8 : NOD1 expression is induced by H.pylori G27 WT sonicate- treated   
                    KATO-III cells at 24h. KATO-III cells (5x10
5
 cells/well) were  
                    stimulated with H.pylori G27 WT sonicate (10 g/ml) or left  
                    unstimulated (medium). Then, cells were harvested at indicated time- 
                    points (6h, 24h, 48h and 72h) and RNA isolations were performed.  
                    Following to RNA isolations, they were converted to cDNA and  
                    analysed for BAFF and 18S rRNA expressions using qRT-PCR. 18S   
                    rRNA was used as endogenous control. Results are graphed using  
                   Graphpad Prism 5.0. p values were determined by Student’s t-test.   
                   Figure 3.8 represents three independent experiments (n=3), n.s.: not   
                   significant. 
NOD1 mRNA expression level was significantly 1.5- fold increased by stimulation 
with H.pylori G27 WT sonicate in KATO-III cells compared to untreated controls at      
24 h. It was observed that NOD1 mRNA expression levels were not significantly 
induced in other indicated time points. This result indicates that NOD1 expression 
levels were induced in H.pylori G27 WT sonicate in KATO-III cells at 24 hours. 
Further experiments were performed at 24 h time-point. 
3.5.2 Effect of H.pylori virulence factor CagA on NOD1 expression  
One of the most important virulence factors of H.pylori Cag A was shown to play a 
role in BAFF and APRIL expression and production. Figure 3.8 indicates that 
H.pylori G27 WT sonicate- treated KATO-III cells express NOD1 at 24 hours. In 
order to assess the role of H.pylori virulence factor Cag A on NOD1 expression, 
KATO-III cells were investigated for NOD1 expression by qRT-PCR (Figure 3.9). 
 
 51 
 
Figure 3.9 : NOD1 expression is significantly increased in H.pylori G27 WT  
                    sonicate treated KATO-III cells. KATO-III cells (5x10
5
 cells/well) were  
                    stimulated for 24 h with H.pylori G27 WT sonicate (10 g/ml), H.pylori  
                    G27 ΔCagA sonicate (10 g/ml) or left untreated (medium). Cells were   
                    harvested at 24 h and RNA isolations were performed. Isolated RNAs   
                    were converted to cDNA and NOD1, 18S rRNA expression levels were   
                    determined by qRT-PCR. 18S rRNA was used endogenous control.    
                    Graphpad Prism 5.0 was used to graph expression levels of NOD1. p    
                    values were determined by Student’s t-test. Data are representative of    
                    three independent experiments (n=3), n.s: not significant. 
NOD1 expression level of H.pylori G27 sonicates- treated KATO-III cells was 
significantly 2-fold increased compared to untreated cells. It was observed NOD1 
expression was not significantly altered in H.pylori G27 ΔCag A sonicate- treated 
KATO-III cells compared to H.pylori G27 WT sonicate- treated cells. Figure 3.9 
indicates that there is no significant effect of Cag A on NOD1 expression. Then, 
research was carried on by investigation of downstream molecules of NOD1 in 
H.pylori sonicates- treated KATO-III cells. 
3.6 Effect of H.pylori G27 WT sonicate on IRF7 expression in KATO-III cells 
3.6.1 Investigation of IRF7 expression from H.pylori G27 WT sonicate treated    
         KATO-III gastric epithelial cells in a time-dependent manner 
NOD1 signalling pathway may lead to expression of type I IFNs from epithelial cells 
[63]. Figure 3.8 showed that NOD1 expression was significantly induced by 
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stimulation of H.pylori G27 WT sonicate in KATO-III cells at 24 h time-point. IRF7 
is a downstream effector of NOD1 and an important transcription factor for 
expression of type I IFNs. In order to understand the H.pylori- induced NOD1 
signalling pathway, KATO-III cells were examined for IRF7 expression by qRT-
PCR (Figure 3.10). 
 
 
Figure 3.10 : Treatment with H.pylori G27 WT sonicate induces IRF7 expression in    
                      KATO-III cells. KATO-III cells (5x10
5 
cells/well) were induced with  
                      H.pylori G27 sonicate (10 g/ml) or left unstimulated (medium).    
                      KATO-III cells were harvested as indicated time-points (6 h, 24 h, 48 h   
                      and 72 h) and RNA isolations were performed. Following RNA   
                      isolations, they were converted to cDNA and analysed for IRF7 and    
                      18S rRNA expressions using qRT-PCR. 18 S rRNA was used as   
                      endogenous control. Results are graphed using Graphpad Prism 5.0.   
                      Statistical analysis was conducted using Student’s t-test. Figure 3.10   
                      represents three independent experiments (n=3), n.s: not significant. 
IRF7 is a downstream molecule of NOD1 and its translocation into nucleus induces 
type I IFNs. According to Figure 3.9, NOD1 expression level was significantly 2-
fold increased after stimulation with H.pylori G27 WT sonicate at 24 h. IRF7 mRNA 
expression level was significantly 2.5-fold induced by stimulation with H.pylori G27 
WT sonicate in KATO-III cells compared to untreated cells at 24 h. It was observed 
that IRF7 mRNA expression levels were not significantly induced in other indicated 
time points except for 6 h time-points (1.2-fold). NOD1 expression leads to induction 
of IRF7 expression at 24 h in H.pylori sonicate- stimulated KATO-III gastric 
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epithelial cell line. Further experiments were performed at 24 h time-point to 
investigate the role of H.pylori virulence factor Cag A on IRF7 expression. 
3.6.2 Effect of H.pylori virulence factor Cag A on IRF7 expression  
In order to understand the role of H.pylori Cag A on the expression of IRF7, KATO-
III cells were investigated for IRF7 expression via qRT-PCR.  
                            
Figure 3.11 : IRF7 expression is significantly increased in H.pylori G27 sonicate  
                      treated KATO-III cells. KATO-III cells (5x10
5 
cells/well) were   
                      stimulated for 24 h with H.pylori G27 WT sonicate (10 μg/ml) and   
                      H.pylori G27 ΔCag A sonicate (10 μg/ml) or left untreated (medium).   
                      Cells were harvested at 24h and RNA isolations were performed.   
                      Isolated RNAs were converted to cDNA and IRF7, 18S rRNA   
                      expression levels were determined by qRT-PCR. IRF7 mRNA   
                      expression levels were normalised to 18S rRNA expression levels.   
                      Results are graphed using Graphpad Prism 5.0. Statistical analysis was  
                      conducted using Student’s t-test. Data are representative of three   
                      independent experiments (n=3), n.s.: not significant. 
According to our results, IRF7 mRNA expression level was significantly 2.5-fold 
increased in H.pylori G27 WT sonicate- treated cells compared to untreated cells. It 
was observed that IRF7 expression level was not significantly altered in H.pylori 
CagA sonicate- treated cells compared to H.pylori G27 WT sonicate- treated cells. 
Figure 3.11 indicates that there is no significant effect of H.pylori virulence factor 
Cag A on IRF7 expression in KATO-III cells. In further experiments, we focus on 
IFN-β expression level in H.pylori sonicates- treated cells. 
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3.7 Role of H.pylori sonicate on IFN-  expressions in KATO-III cells 
3.7.1 Investigation of IFN-  expression from H.pylori G27 WT sonicate treated 
KATO-III gastric epithelial cells in a time-dependent manner 
IRF7 induces the expression of IFN- , which is a member of type I IFNs. Previous 
studies have shown that IFN-  induces BAFF expression in monocytes, 
macrophages, dendritic cells, salivary gland epithelial cells and airway epithelial 
cells [66,75]. In order to determine IFN-  expression in a time-dependent manner, 
IFN-  expression from H.pylori- treated gastric epithelial KATO-III cells were 
examined by using qRT-PCR (Figure 3.12). 
 
 
Figure 3.12 : H.pylori G27 WT sonicate induces IFN-  expression in KATO-III cells   
                      at 24 h. KATO-III cells (5x 10 
5 
cells/well) were induced with H.pylori   
                      G27 WT sonicate (10 g/ml) or left unstimulated (medium). Then,   
                      KATO-III cells were harvested as indicated time-points (6 h, 24 h, 48 h   
                      and 72 h) and RNA isolations were performed. Following to RNA   
                      isolations, they were converted to cDNA and analysed for IFN-  and    
                      18S rRNA expressions using qRT-PCR. 18S rRNA was used as   
                      endogenous control. Graphpad Prism 5.0 was used to graph expression   
                      levels of IFN- . p values were determined by Student’s t-test. Figure   
                      3.12 represents three independent experiments (n=3), n.s: not   
                      significant.  
According to IFN-  qRT-PCR results, IFN-β beta expression was significantly 4-
fold increased in KATO-III cells when they were treated with H.pylori G27 WT 
sonicate compared to untreated controls at 24 h time-point. Correlating with 
significant increase of NOD1 (Figure 3.8) and IRF7 expression levels (Figure 3.10) 
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by stimulation with H.pylori G27 WT sonicate for 24 h, IFN-β mRNA expression 
was also found to be significantly elevated at 24 h upon treatment with H.pylori G27 
sonicate. Overall, these results indicate that H.pylori G27 WT sonicate may induce 
IFN-β expression through NOD1-IRF7 signalling.  
3.7.2 Effect of H.pylori virulence factor Cag A on IFN- β expression  
Figure 3.12 indicates the increase of IFN- β expression when KATO-III cells were 
treated with H.pylori G27 WT sonicate at 24 h. Then we aimed to understand the 
role of H.pylori virulence factor of Cag A on IFN-  expression in KATO-III cells. 
For this purpose, KATO-III cells were investigated for IFN-  expression by qRT-
PCR (Figure 3.13) 
 
                  
 Figure 3.13: IFN- β expression level is significantly decreased in H.pylori G27 
Cag A sonicate treated KATO-III cells at 24h. KATO-III cells (5x10 
5 
cells/well) 
were induced for 24 h with H.pylori G27 WT (10 g/ml) sonicate and H.pylori G27 
ΔCag A sonicate (10 g/ml) or left untreated (medium). Cells were harvested at 24 h 
and RNA isolations were performed. Isolated RNAs were converted to cDNA and 
IFN-β, 18S rRNA expression levels were determined by qRT-PCR. IFN- β were 
normalized to 18 S rRNA expression levels. Graphpad Prism 5.0 was used to graph 
expression levels of IFN- β. p values were determined by Student’s t-test. Data are 
representative of three independent experiments (n=3), n.s: not significant. 
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According to IFN- β qRT-PCR results, IFN-β mRNA expression level was 
significantly 4-fold increased in H.pylori G27 WT sonicate- treated cells compared 
to untreated cells. It was also observed that IFN- β expression level was also 
significantly induced (2-fold) in H.pylori G27 ΔCag A sonicate- treated cells but not 
as much as H.pylori G27 WT sonicate- treated cells. This results show that Cag A 
has a role on IFN-β expression. 
3.8 Investigation of JAK/STAT signalling pathway in H.pylori G27 WT sonicate      
      treated KATO-III cells 
3.8.1 Effect of H.pylori G27 WT sonicate on STAT1 Phosphorylation   
Previous studies have shown that IFN- β expression induces high expression of 
BAFF in airway epithelial cells and salivary gland cells in an autocrine/paracrine 
pathway. It was also reported that BAFF expression and secretion was found to be 
dependent on JAK/STAT signalling pathway in these epithelial cells [66,75]. In our 
study, it was aimed to investigate JAK/STAT signalling pathway on BAFF 
expression and production from H.pylori G27 WT sonicate- stimulated gastric 
epithelial cell line, KATO-III. In order to assess the STAT1 phosphorylation, we 
used specific JAK inhibitor I (JAKI) which inhibits STAT1 activation (Figure 3.14). 
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Figure 3.14 : Treatment with H.pylori G27 WT sonicate induces STAT1    
                       phosphorylation in KATO-III cells. KATO-III cells were either pre- 
                       incubated with 1 or 10 μM JAKI for 1 h and then stimulated with  
                       H.pylori G27 WT sonicate (10 μg/ml) for 24 h or stimulated with  
                       H.pylori G27 WT sonicate (10 μg/ml) without pre-treatment with  
                       JAKI or left untreated (medium). Protein isolations were performed  
                       and lysate samples were loaded on gel as 20 μg and immunoblotted for  
                       anti-phophoSTAT-1antibody. Phosphorylation levels of STAT1 were  
                       determined by using Western Blotting. Phospho- STAT1 bands were  
                       normalized to total STAT1 protein levels. Graphpad Prism 5.0 was  
                       used to graph expression levels of IFN- β. p values were determined  
                       by Student’s t-test. Data are representative of two independent  
                       experiments (n=2), n.s: not significant.  
Figure 3.14 shows that STAT1 phosphorylation was increased from 80% to 100% in 
H.pylori G27 WT sonicate- treated KATO-III cells compared to untreated control. 
Phosphorylation of STAT1 was reduced in 1 M JAKI and 10 M JAKI pre- treated 
and H.pylori G27 WT sonicate- stimulated KATO-III cells compared to H.pylori 
G27 WT sonicate- treated cells (42%, 38% respectively). These results demonstrate 
the efficiency of JAKI on blocking phosphorylation of STAT1.  
3.8.2. Effect of JAKI on BAFF expression  
It is known that JAK/STAT signalling pathway plays a role in IFN-  secretion via 
IFNARs. BAFF is produced by JAK/STAT signalling pathway in airway epithelial 
cells [66]. In order to investigate the role of JAK/STAT signalling pathway on BAFF 
expression, BAFF expression levels of H.pylori G27 WT sonicate- stimulated 
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KATO-III cells (either pre-treated with JAKI or not) were determined by qRT-PCR 
(Figure 3.15). 
 
 
 
Figure 3.15 : Treatment with JAKI inhibits BAFF expression in KATO-III cells.    
                       KATO-III cells (5x 105 cells/well) were either pre-incubated with 1 or  
                       10 μM JAKI for 1 h and then stimulated with H.pylori G27 WT   
                       sonicate (10 μg/ml) for 24 h or stimulated with H.pylori G27 WT   
                       sonicate (10 μg/ml) without pre-treatment with JAKI or left untreated  
                       (medium). Isolated RNAs were converted to cDNA and BAFF, 18S  
                       rRNA expression levels were determined by qRT-PCR. 18S rRNA  
                       was used as endogenous control. BAFF mRNA expression levels were  
                       normalised to 18S rRNA. Results are graphed using Graphpad Prism  
                       5.0. Statistical analysis was conducted using Student’s t-test. Data are  
                       representative of three independent experiments (n=3), n.s.: not  
                       significant. 
Figure 3.15 shows that BAFF expression was dependent on JAK/STAT signalling 
pathway in H.pylori G27 WT sonicate- stimulated gastric epithelial cell line KATO-
III. JAK1 inhibits STAT1 phosphorylation and BAFF expression levels were 
decreased in the presence of JAKI. BAFF expression level of H.pylori G27 WT 
sonicate- treated cells was significantly increased compared to untreated control (3-
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fold). BAFF expression from H.pylori G27 WT sonicate- treated KATO-III cells 
with 1 M pre-treated JAKI was significantly decreased compared to H.pylori G27 
WT sonicate- treated cells. When KATO-III cells were pre-incubated with 10 M 
JAKI, BAFF expression level was significantly decreased compared to 1 M pre-
treated JAKI with H.pylori G27 WT sonicate- treated cells and H.pylori G27 WT 
sonicate- treated cells. BAFF mRNA expression level of 10 μM JAKI pre-treated and 
H.pylori G27 WT sonicate- stimulated KATO-III cells was similar to untreated 
control cells.  
3.8.3. Effect of JAKI on BAFF production 
In order to investigate the importance of JAK/STAT signalling pathway on H.pylori 
G27 WT sonicate- stimulated KATO-III cells, BAFF production from these cells 
were determined using Western Blotting (Figure 3.16). 
 
 
 
 
 
                    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 : mBAFF and sBAFF protein levels were decreased in the presence of   
                      JAKI.   
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Figure 3.16 (cont’d ): KATO-III cells (5x 105 cells/well) were either pre-    
                                   incubated with 1 or 10 μM JAKI for 1 h and then stimulated    
                                   with H.pylori G27 WT sonicate (10 μg/ml) for 24 h or     
                                   stimulated with H.pylori G27 WT sonicate (10 μg/ml) without   
                                   pre-treatment with JAKI or left untreated (medium). KATO-III   
                                   cells were harvested for protein isolations. Culture supernatants   
                                   and lysate samples concentrations were measured by BCA   
                                   assay kit. Samples were loaded on gel as 20 μg. mBAFF and  
                                   sBAFF levels were analysed by using Western Blotting.   
                                   Densitometric analysis was performed by using GAPDH as   
                                   endogenous controls for mBAFF. Ponceau S was used for   
                                   normalizing sBAFF protein levels. Results are graphed using  
                                   Graphpad Prism 5.0. Statistical analysis was conducted using   
                                   Student’s t-test. Data are representative of two independent   
                                   experiments (n=2), n.s: not significant.  
According to membrane-bound BAFF (mBAFF) Western Blotting results, BAFF 
production was significantly 1.3-fold increased in H.pylori G27 WT sonicate- treated 
cells compared to untreated KATO-III cells. Both pre-treatment with 1 M JAKI or 
10 M JAKI significantly inhibited mBAFF production level compared to H.pylori 
G27 WT sonicate- treated cells. Soluble BAFF (sBAFF) Western Blotting results 
also showed that sBAFF was significantly 1.6-fold increased in H.pylori G27 
sonicate- treated cells compared to untreated control. In a dose-dependent manner of 
pre-treatment of JAKI, sBAFF protein levels were significantly inhibited compared 
to H.pylori G27 WT sonicate- treated cells. These results suggest that JAK/STAT 
signalling pathway is important in BAFF expression and production from H.pylori 
G27 WT sonicate- treated KATO-III cells.  
3.8.4 Investigation of JAKI on BAFF secretion  
Figure 3.15 and Figure 3.16 showed that JAKI has an inhibitory effect on BAFF 
expression and production. In order to verify the inhibition of JAKI on BAFF 
secretion, BAFF ELISA was performed in JAKI pre-treated and then stimulated with 
H.pylori G27 WT sonicate- induced KATO-III cells (Figure 3.17). 
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Figure 3.17 : BAFF secretion levels were decreased in JAKI treated KATO-III cells.   
                       KATO-III cells (5x 105 cells/well) were either pre-incubated with 1 or   
                       10 μM JAKI for 1 h and then stimulated with H.pylori G27 WT   
                       sonicate (10 μg/ml) for 24 h or stimulated with H.pylori G27 WT   
                       sonicate (10 μg/ml) without pre-treatment with JAKI or left untreated   
                       (medium). Secreted BAFF levels were detected by ELISA in culture   
                       supernatants of KATO-III cells. Results are graphed using Graphpad   
                      Prism 5.0. Statistical analysis was conducted using Student’s t-test.  
BAFF ELISA results showed the similar pattern with BAFF expression and BAFF 
production results in the presence of JAKI. According to BAFF ELISA results, 
BAFF secretion was significantly 3.5-fold increased in H.pylori G27 WT sonicate- 
treated KATO-III cells when compared to untreated control. Dose –dependent JAKI 
treatment were found to result in significant inhibition of secreted BAFF levels when 
compared to H.pylori G27 WT sonicate- treated cells. Overall, our results show that 
JAKI inhibits the BAFF secretion from gastric epithelial cell line KATO-III at 24 h 
time-point. In addition to that, BAFF secretion is dependent on JAK/STAT 
signalling pathway in gastric epithelial cells like airway epithelial cells. 
3.8.5. Effect of JAKI on APRIL expression 
Inhibition effect of JAKI on BAFF expression was shown in figure 3.15.  JAK1 is an 
essential factor for BAFF expression, it was continued by investigating APRIL 
signalling pathway in H.pylori G27 WT sonicate- stimulated KATO-III cells.  For 
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this purpose, APRIL mRNA expression levels were determined by qRT-PCR in 
JAKI pre-treated and H.pylori G27 WT sonicate- induced KATO-III cells (Figure 
3.18). 
 
Figure 3.18 : Treatment with JAKI inhibits APRIL expression in KATO-III cells.  
                       KATO-III cells (5x 10
5 
cells/well) were either pre-incubated with 1 or   
                       10 M JAKI for 1 h and then stimulated with H.pylori G27 WT   
                       sonicate (10 g/ml) for 24 h or stimulated with H.pylori G27 WT   
                       sonicate (10 g/ml) without pre-treatment with JAKI or left untreated   
                       (medium). Cells were harvested after 24 and RNA isolations were  
                       performed. Isolated RNAs were converted to cDNA. APRIL and 18S   
                       rRNA expression levels were determined by qRT-PCR. APRIL   
                       mRNA expression levels were normalized to 18 S rRNA expression   
                       levels. Graphpad Prism 5.0 was used to prepare the graphs   
                       representing the expression levels of APRIL. p values were   
                       determined by Student’s t-test. Data are representative of three   
                       independent experiments (n=3). 
Our data suggests that JAK/STAT signalling pathway induces APRIL expression 
from H.pylori G27 WT sonicate- treated KATO-III cells at 24 h time-point. APRIL 
expression level was significantly 1.3-fold increased in H.pylori G27 WT sonicate- 
treated KATO-III cells compared to untreated cells. It was observed that JAKI 
inhibits APRIL expression from KATO-III cells. This result suggests that APRIL is 
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also expressed through by JAK/STAT signalling pathway in gastric epithelial cell 
line KATO-III when treated with H.pylori G27 WT sonicate. 
3.8.6. Effect of JAKI on APRIL production  
Following APRIL expression analysis in JAKI studies, in order to understand the 
effect of JAKI on APRIL production, APRIL protein levels were investigated in 
JAKI pre- incubated and H.pylori G27 WT sonicate-stimulated KATO-III cells at 24 
h time-point (Figure 3.19) 
 
             
 
           
Figure 3.19 : APRIL protein levels were decreased in JAKI treated KATO-III cells.   
                      KATO-III cells (5x 10
5 
cells/well) were either pre-incubated with 1 or   
                      10 M JAKI for 1 h and then stimulated with H.pylori G27 WT  
                      sonicate (10 g/ml) for 24 h or stimulated with H.pylori G27 WT   
                      sonicate (10 g/ml) without pre-treatment with JAKI or left untreated   
                      (medium). KATO-III cells were harvested for protein isolations.   
                     Densitometric analysis was performed by using GAPDH as endogenous   
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              controls for APRIL protein. Graphpad Prism 5.0 was used to prepare the   
              graphs representing the production levels of APRIL. Data are representative   
              of two independent experiments (n=2), n.s.: not significant.  
According to APRIL Western Blotting results, it was observed that JAKI have an 
also inhibitory effect on APRIL production in 24 h time-point. APRIL production 
was significantly 1.3-fold increased in H.pylori G27 WT sonicate- treated cells 
compared to untreated cells. JAKI treatment in dose-dependent manner (1-10 M 
JAKI) showed a significant decrease in APRIL production from KATO-III cells. 
APRIL production level in KATO-III cells pre-treated with 10 M JAKI and 
stimulated with H.pylori G27 WT sonicate was decreased compared to untreated 
cells. These results suggest that H.pylori G27 WT sonicate- treated KATO-III cells 
produce APRIL via JAK/STAT signalling pathway. 
3.8.7. Effect of JAKI on NOD1 expression  
Inhibitory effect of JAKI on NOD1 has not been investigated yet. Figure 3.8 shows 
that NOD1 expression is significantly 2-fold increased in H.pylori G27 WT sonicate- 
treated KATO-III cells compared to untreated cells. In order to assess the effect of 
JAKI on NOD1 expression, KATO-III cells were investigated for NOD1 expression 
by qRT -PCR (Figure 3.20). 
 
 
 
Figure 3.20 : JAKI inhibits NOD1 expression in KATO-III cells.  
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Figure 3.20 (cont’d): KATO-III cells (5x105 cells/well) were either pre-incubated   
                                    with 1 or 10 M JAKI for 1 h and then stimulated with   
                                    H.pylori G27 WT sonicate (10 g/ml) for 24 h or stimulated   
                                    with H.pylori G27 WT sonicate (10 g/ml) without pre-  
                                    treatment with JAKI or left untreated (medium). Isolated  
                                    RNAs were converted to cDNA. NOD1 and 18S rRNA     
                                    expression levels were determined by qRT-PCR. 18S rRNA    
                                    was used as endogenous control. Results are graphed using   
                                    Graphpad Prism 5.0. Statistical analysis was conducted using    
                                    Student’s t-test.  Data are representative of two independent  
                                    experiments (n=2). 
According to qRT-PCR results of NOD1 expression, H.pylori G27 WT sonicate- 
treated cells express significantly 2-fold increased levels of NOD1 compared to 
untreated cells. It was observed that the pre-treatment with JAKI in dose-dependent 
manner inhibits NOD1 expression in H.pylori G27 WT sonicate-stimulated KATO-
III cells. This study needs further experiments to understand the JAKI effect on 
NOD1 expression. 
3.8.8. Effect of JAKI on the expression of IRF7  
IRF7 translocation into nucleus is known to be important for IFN-  expression in 
epithelial cells. IFN-  can bind to its receptor on the cell surface and induce Th1 
cytokines and its own production through JAK/STAT signalling pathway and also 
induces BAFF expression in epithelial cells [66,75] (Figure 1.9). In order to 
understand the effect of JAKI on IRF7 expression, KATO-III cells were investigated 
for expression of IRF7 in RNA level (Figure 3.21) 
 
 
Figure 3.21 : IRF7 expression is decreased in JAKI treated KATO-III cells.  
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Figure 3.21 (cont’d): KATO-III cells (5x 105 cells/well) were either pre-incubated    
                                     with 1 or 10 M JAKI for 1 h and then stimulated with   
                                     H.pylori G27 WT sonicate (10 g/ml) for 24 h or stimulated   
                                     with H.pylori G27 WT sonicate (10 g/ml) without pre- 
                                     treatment with JAKI or left untreated (medium). Cells were   
                                     harvested and RNA isolations were performed. Isolated   
                                     RNAs were converted to cDNA. IRF7 and 18S rRNA   
                                     expression levels were determined by qRT-PCR. RF7 mRNA   
                                     expression levels were normalised to 18S rRNA expression   
                                     levels. Results are graphed using Graphpad Prism 5.0.  
                                     Statistical analysis was conducted using Student’s t-test. Data   
                                     are representative of two independent experiments (n=2). 
Figure 3.21 indicates that IRF7 expression level was significantly 2-fold increased in 
H.pylori G27 WT sonicate- treated KATO-III cells compared to untreated cells. 
IRF7 expressions from JAKI pre-treated KATO-III cells were significantly inhibited 
compared to H.pylori G27 WT sonicate- treated KATO-III cells at 24 h time-point. 
This result suggests that JAKI significantly inhibits IRF7 expression in KATO-III 
cells. 
 
3.8.9. Role of JAKI on IFN-  expression 
Published studies showed that IFN-  beta secretion is involved in JAK/STAT 
signalling pathway [66,75]. It was also reported that IFN-  induces high levels of 
BAFF expression in epithelial cells. In order to assess the effect of JAKI on IFN-  
expression, KATO-III cells were investigated for IFN-  expression by qRT-PCR 
(Figure 3.22). 
 
 
 
 
 
                      
Figure 3.22 : IFN-  expression is decreased in JAKI treated KATO-III cells.  
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Figure 3.22 (cont’d): KATO-III cells (5x 105 cells/well) were either pre-incubated   
                                     with 1 or 10 M JAKI for 1 h and then stimulated with  
                                     H.pylori G27 WT sonicate (10 g/ml) for 24 h or stimulated   
                                     with H.pylori G27 WT sonicate (10 g/ml) without pre- 
                                     treatment with JAKI or left untreated (medium). Cells were   
                                     harvested and RNA isolations were performed. Isolated   
                                     RNAs were converted to cDNA. IFN-  and 18S rRNA           
                                     expression levels were determined by qRT-PCR. IFN-    
                                     expression levels were normalized to 18S rRNA expression   
                                     levels. Results are graphed using Graphpad Prism 5.0.   
                                     Statistical analysis was conducted using Student’s t-test. Data     
                                     are representative of two independent experiments (n=2). 
 
According to qRT-PCR results of IFN-β expressions, it was observed that IFN-β 
expression was significantly 2-fold increased in H.pylori G27 WT sonicate- treated 
KATO-III cells compared to untreated control. The increase in IFN-β mRNA 
expression levels in H.pylori G27 WT sonicate- treated cells were significantly 
inhibited by both 1 M JAKI or 10 M JAKI treatment. It is known from the 
published studies that IFN-beta is expressed by JAK/STAT signalling pathway in 
epithelial cells. This study also showed that JAK/STAT signalling pathway has a role 
in IFN-β expression. Figure 3.22 shows the effect of JAKI on IFN-β expression in 
RNA level. 
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4.DISCUSSION AND CONCLUSION 
TNF family members, BAFF and APRIL are the regulator and activator cytokines 
for B cells. BAFF is expressed by monocytes, macrophages, activated-T cells, 
dendritic cells, epithelial cells and cancer cells. APRIL is also produced by immune 
cells such as macrophages, monocytes, dendritic cells, T cells and also non-immune 
cells such as epithelial cells [36,37,43]. APRIL has also a role in stimulation of 
tumour growth. Elevated levels of BAFF and APRIL have been found in several 
autoimmune diseases such as rheumatoid arthritis (RA), Sjögren’s syndrome (SS), 
experimental autoimmune encephalomyelitis (EAE), systemic lupus erythematosus 
(SLE) and autoimmune thyroid disease [37,38,39,40]. 
Different forms of BAFF have been characterized. First of all, BAFF is synthesized 
as membrane–bound form and then cleaved from the cell surface by furin convertase. 
Therefore, it can both exist as a membrane-bound (32 kDa) and soluble form 
(17kDa). This TNF family cytokine can form a homodimer, heterodimer, 20 –mer 
and 60-mer forms to bind its receptors on the cell surface [36,41]. BAFF expression 
and secretion from Helicobacter pylori–infected gastric epithelial cell line was 
shown in this study. In order to understand the importance of Cag A virulence factor 
on BAFF expression, KATO-III cells were stimulated with H.pylori G27 (WT) and 
its isogenic Cag A mutant ( Cag A) at 24 h time-point. Quantitative Realtime- PCR 
results indicated that BAFF was significantly increased in Helicobacter pylori G27 
(WT) when compared to untreated control cells, whereas BAFF expression was 
found to be significantly inhibited in H.pylori G27 CagA-treated KATO-III cells 
compared to H.pylori G27 WT- treated cells (Figure 3.2). In order to investigate 
BAFF production from H.pylori- treated KATO-III cells, Western Blotting and 
ELISA experiments were performed. Both membrane-bound and soluble forms of 
BAFF were shown in Western Blotting experiments (Figure 3.3). These results 
correlated with the results of BAFF mRNA expression levels. Both membrane-bound 
and soluble forms of BAFF were significantly increased in H.pylori G27- treated 
KATO-III cells compared to H.pylori G27 CagA- treated KATO-III cells and 
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untreated controls in protein levels. The role of Cag A, which is one of the most 
important virulence factors of H.pylori, on BAFF expression and secretion from 
gastric epithelial cell line was shown in this study. APRIL, a homologue of BAFF, 
was significantly increased in both RNA and protein level in H.pylori G27 WT 
sonicate- treated KATO-III cells compared to untreated control cells. Like in the case 
of BAFF, lack of Cag A leads to decrease of APRIL both in RNA and protein levels 
(Figure 3.7). These results suggest that expression and secretion of BAFF and 
APRIL from gastric epithelial cells depend on the presence of H.pylori virulence 
factor CagA.  
NOD1 is a NLR family member expressed by antigen-presenting cells and gastric 
epithelial cells. It has been reported that NOD1 plays an important role for innate 
immune response in gastric epithelial cells against Helicobacter pylori [62].  NOD1 
is an intracellular key receptor for recognition of PAMPs and DAMPs. NOD1 can be 
activated by the peptides derived from peptidoglycan (PGN), which is present in 
most of the gram-negative bacteria. H.pylori can deliver its PGN into host cell by 
using Type-IV secretion system or outer membrane vesicles and induce NOD1 
activation [65]. Upon ligand binding, NOD1 becomes activated and induce activation 
of down-stream molecule RICK. Activated RICK can both interact with TAK1 or 
TRAF3. Activation of TAK1 induces NF- B pathway. Interaction between RICK 
and TRAF3 activates TBK1 and induces IRF7, a transcription factor for type I 
interferons, expression that leads to production of IFN- . Secreted IFN-  binds to its 
IFNARs on the cell membrane and activates JAK/STAT signalling pathway and 
induce secretion of Th1 cytokines and IFN-  (Figure 1.9). 
Recently it was reported that IFN-  induce BAFF production from airway epithelial 
cells and salivary gland cells [66,75]. In order to investigate the role of NOD1 
signalling pathway in BAFF expression and BAFF production from H.pylori- treated 
KATO-III cells, NOD1, downstream IRF7 and IFN-β expression levels were 
examined by qRT-PCR in this study. qRT-PCR results demonstrated that NOD1 
expression was increased in H.pylori G27 WT sonicate- treated  KATO-III cells 
(Figure 3.9). Moreover, H.pylori G27 WT sonicate- induced IRF7 expression in 
RNA level (Figure 3.11). In parallel with IRF7 expression levels, IFN-  mRNA 
expression levels were also increased in H.pylori G27 WT sonicate- treated cells 
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compared to untreated control cells (Figure 3.13). Therefore, involvement of IFN-  
in BAFF and APRIL production from gastric epithelial cells may be speculated.  
The effect of JAK inhibitor (JAKI) on BAFF production in airway epithelial cells 
has been recently demonstrated [66]. In this study, we have shown that STAT1 
phosphorylation levels were significantly inhibited in the presence of increasing 
doses of JAKI (Figure 3.14). BAFF expression and protein levels were also 
significantly inhibited by JAKI in a dose –dependent manner in KATO-III cells. 
BAFF expression was highly increased in H.pylori G27 WT sonicate- treated 
KATO-III cells whereas pre-treatment with JAKI significant inhibited this increase 
in BAFF expression and production. Western Blotting and qRT-PCR results 
demonstrated that APRIL was significantly inhibited in both RNA and protein level 
in the presence of JAKI (Figures 3.18 and 3.19). These results suggest that 
production of BAFF and APRIL is mediated by JAK/STAT signalling pathway in 
H.pylori G27 WT sonicate- treated KATO-III cells. 
In the light of this study, induction of BAFF expression and production in H.pylori 
G27 WT sonicate- stimulated may be mediated by IFN-β. IFN-β is induced by 
possibly PGNs of H.pylori which in turn leads to its own production of IFN-β along 
with BAFF and APRIL through interaction with IFNARs (Figure 4.1). Silencing of 
IFNARs with relevant siRNAs may provide more information regarding IFN-β 
dependent BAFF signalling. Intracellular signalling mechanism(s) of IFN-β mediated 
BAFF expression still remain unclear. In order to elucidate the induction of IFN-β in 
H.pylori sonicate stimulated KATO-III cells, H.pylori derived PGNs can be 
investigated further. 
In this study, the effect of JAKI on NOD1 expression was also demonstrated for the 
first time. In order to elucidate the intracellular mechanisms of NOD1 signalling in 
BAFF expression further studies including siRNA silencing of NOD1 and 
determining phosphorylation levels of RICK (a downstream molecule of NOD1) 
may be performed.  
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Figure 4.1 : Proposed model of BAFF and APRIL expression in H.pylori G27 WT        
                    sonicate- treated KATO-III cells. PGNs of H.pylori can induce NOD1  
                    expression and IRF7 translocation to nucleus. IRF7 initiates IFN-β   
                    expression from KATO-III cells. Secreted IFN-β binds to its own  
                    receptor on the cell surface and initiates JAK/STAT signalling pathway.   
                    BAFF expression is possibly dependent on IFN-β mediated JAK/STAT       
                    signalling. 
These studies may be also repeated in primary gastric epithelial cells and the effect 
of BAFF and APRIL, which were secreted from gastric epithelial cells, on B cell 
survival and proliferation can be investigated in further studies.  
In conclusion, this study has significant contribution to literature since it shows for 
the first time the involvement of Cag A virulence factor on BAFF and APRIL 
expression and importance of JAK/STAT signalling pathway on production of these 
cytokines from H.pylori G27 WT sonicate treated gastric epithelial cell line, KATO-
III. 
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